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Abstract 
 
ELIZA J.R. PETERSON: Evolution and Prevention of Antibiotic Resistance: Small 
Molecule Inhibitors of Bacterial Recombination Enzymes 
(Under the direction of Scott F. Singleton) 
 
Antibiotic resistant bacteria are an ever-increasing problem for the modern 
chemotherapy of bacterial infectious diseases.  The loss of effective antibiotic therapies 
due to antibiotic resistance and the withering antibiotic pipeline are resulting in a 
reemergence in deaths from bacterial infections.  New strategies are needed to combat 
pathogenic bacteria and in this context bacterial targets involved in the development of 
resistance are emerging an intriguing candidates for inhibition studies.  Recent evidence 
suggests that bacterial stress response pathways (i.e., SOS and competence for 
transformation) are responsible for accelerated genetic changes that ultimately establish 
antibiotic resistance.  Intervening in these pathways by small molecule inhibition of key 
recombination enzymes, RecA and EndA, would impact the DNA repair, SOS 
mutagenesis and recombination-based horizontal gene transfer activities of these 
enzymes and hinder the acquisition of antibiotic resistance.  Bacteria having loss-of-
function mutations in the recA gene are more sensitive to antibiotic treatment and 
develop resistance more slowly or not at all.  In addition, endA-null strains of S. 
pneumoniae have diminished transformation efficiencies and are unable to acquire 
resistance-conferring DNA.  Therefore, we believe chemotherapeutic agents that impart 
these bacterial phenotypes could act synergistically with currently prescribed antibiotics 
 iii 
to prevent the accumulation of populations that are resistant to them.  Towards this goal, 
we sought to identify properly designed inhibitors of RecA and EndA.  High-throughput 
screening (HTS) is recognized as a powerful tool in drug discovery to identify target-
specific lead compounds.  We developed rational high-throughput screening programs to 
discover small-molecule inhibitors of RecA and EndA.  Through these studies, we have 
identified novel chemical classes that specifically target RecA or EndA and demonstrate 
that these  enzymes hold potential as novel targets in the treatment of bacterial infections. 
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Chapter 1 
Introduction 
1.1. Challenges of antibacterial discovery 
 
The introduction of penicillin in the 1930s opened up the era of antibiotics
1
and is 
heralded as one of the greatest discoveries in the history of medicine.  Without question, 
since its introduction in the early twentieth century, antibacterial chemotherapy has 
substantially reduced the burden of disease caused by bacterial infections.
 2
 However, the 
widespread emergence of antibiotic resistance in bacteria has occurred as a consequential 
response and severely compromises the therapeutic efficacy of the antibiotics once seen 
as huge successes.  Today, antibiotic resistance is recognized as a major challenge for the 
health of the human population.
3
 
Infection by antibiotic-resistant bacteria is a serious threat to public health.  In the 
United States, nearly 2 million people acquire bacterial infections in hospitals each year, 
and about 99,000 die as a result.
 4
 Hospital-acquired infections (HAI) kill more people 
than HIV-AIDS, diabetes, emphysema, Parkinson’s disease or homicide each year, with a 
total cost of treatment at $5.7–6.8 billion per year. 5  Importantly, about 70% of HAIs are 
resistant to at least one of the major classes of antibiotics and 16% are resistant to 
multiple antibiotic classes.
 6
 Patients infected with drug-resistant organisms are extremely 
costly to our healthcare system by extending the average length of stay, making low cost 
drugs ineffective, and allowing secondary illnesses to progress faster.
 7
  From this, it is 
 2 
evident that antibiotic resistance in pathogenic bacteria has enormous human and 
economic consequences.   
Infections with resistant bacteria were first reported over 60 years ago,
 8
 and since 
the 1980s, the incidence of resistant bacteria has increased dramatically (Figure 1.1).  As 
resistance increases, it limits the treatment options available to healthcare providers.  This 
requires the development of new antibacterial agents, but the discovery of such is not 
proving to be an easy task.  The “golden era” when novel secondary metabolites were 
easily identified is over and modern approaches to develop antibiotic drugs have had only 
limited success.
 9
 Only 13 new oral or intravenous antibiotics have been approved since 
1998 (Figure 1.1).
 7
 This low output of novel drugs has resulted in the downsizing or 
ending of many industrial research efforts.  Taken together, the alarming rise in antibiotic 
resistant bacterial strains and the diminishing supply of new antibiotics are disturbing 
trends that are intersecting with dangerous consequences (Figure 1.1). The goal behind 
the work undertaken in this dissertation aimed to increase our knowledge of bacterial 
recombination enzymes in the development of antibiotic-resistant bacterial infectious 
diseases and potentially present RecA and EndA as novel therapeutic targets for 
prevention.  
 
 3 
 
 
Figure 1.1. Dangerous antibiotic-related trends.  Left panel: The % incidence increase in 
nosocomial infections involving methicillin-resistant Staphylococcus aureus (MRSA), 
vancomycin-resistant Enterococci (VRE) and fluoroquinolone-resistant Pseudomonas aeruginosa 
(FQRP) in the past 30 years. Right Panel: The decreasing number of approved antibiotics in a 
similar time span. 
 
1.2. A revised model for accelerated evolution of antibiotic resistance 
 
Antibiotic resistant strains of bacteria emerge when genetic changes allow 
individual bacteria to escape antibiotic killing, thereby surviving and propagating their 
resistance to subsequent generations.  Bacteria become resistant to antibiotics by 
acquiring one of several common molecular strategies: (1) drug inactivation, (2) 
modification of the drug target, and (3) decreasing the amount of drug reaching the target 
(usually by modifying influx/efflux pump expression).
 10
 In all of these cases, a heritable 
change in the bacteria’s DNA is required.  Such alterations to the bacterial genome occur 
through local changes in the DNA sequence (de novo mutation), intrachromosomal 
shuffling of DNA sequences (recombination), or the acquisition of exogenous DNA from 
other organisms (horizontal gene transfer; e.g., through mobile genetic elements such as 
 4 
plasmids, transposons or pathogenicity islands or through natural transformation 
mediated via competence). 
Regardless of the mechanism, genetic change has conventionally been viewed as 
a purely passive process (e.g., mutations occur randomly, Figure 1.2, top panel).  
However, recent studies demonstrate that bacteria actively promote their own genetic 
diversification and, importantly, the rate of genetic change increases dramatically when 
bacteria are exposed to antibiotics (Figure 1.2, bottom panel).
 11-14
 These accelerated 
genetic changes can lead to the evolution
11
 and spread
15
 of antibiotic resistance as well as 
the production and dissemination of virulence factors.
 16-19
 In this way, antibiotics not 
only select for resistant strains of bacteria by killing their sensitive neighbors, but also 
accelerate the emergence of such resistant bacteria in the first place.  Interestingly, a 
report nearly 50 years ago observed that antibiotics “catalyze” bacteria to take on “the 
resistant character.” 20 There was little follow-up at the time, but today it has been clearly 
shown that antibiotic-induced stress increases the frequency and efficacy of evolutionary 
activities
11,14,21
 and that key bacterial recombination enzymes are important for the 
heritable DNA changes that allow bacteria to become antibiotic resistant.
15,22-25
 
 
 
 5 
 
 
Figure 1.2. The conventional and revised pathways leading to resistant bacteria.  Top 
panel: the conventional model depicts antibiotics selecting for preexisting resistant variants (red 
cells).  Bottom panel: in contrast, the revised model shows antibiotics accelerating the presence of 
resistant variants by inducing accelerated mutagenesis (resistant blue cells) and gene transfer 
(green cells that acquired green resistance genes).  
  
1.3. The role of recombination enzymes in accelerated evolution of antibiotic 
resistance 
 
As introduced above, bacterial genetic diversification is accelerated in the 
presence of antibiotics.  Changes in the bacterial genome occur through induced mutation, 
intrachromosomal recombination, and the acquisition of foreign DNA.  Moreover, these 
genetic changes originate from bacterial processes that couple antibiotic stress with 
accelerated bacterial evolution.  These processes are programmed stress responses that 
allow bacteria to cope with the effects of DNA damage caused by antibacterial agents, 
known as the SOS response and competence for transformation (a.k.a., SOS and 
competence).  While SOS and competence differ by bacterial species and other details, 
they both are induced by antibiotics and lead to activities that promote genetic diversity.
 
26
  In addition, both pathways are tightly regulated by the bacteria and depend on the 
function of select recombination enzymes, such as RecA and EndA.  The following three 
subsections outline (1) the induction of SOS and competence by antibiotics and how the 
 6 
distinct activities of (2) RecA and (3) EndA promote genetic diversity and resistance 
development in response to antibiotic-induced stress (Figure 1.3). 
 
 
 
Figure 1.3. The molecular models for antibiotic accelerated evolution of resistance.  
Left panel: antibiotic-induced DNA damage activates RecA leading to induced (SOS) 
mutagenesis and increased intrachromosomal recombination.  Right panel: antibiotic induction of 
competence for transformation via EndA-RecA leads to horizontal gene transfer. 
 
1.3.1. Induction of the SOS response and competence for transformation by antibiotics  
 
While many naturally occurring phenomena can cause bacterial stress and initiate the 
SOS response and competence for transformation, it has been shown that antibiotic treatment 
serves as a powerful instigator of SOS and competence (Table 1.1). 11,14,15,21,22,25,27-33 For 
example, ciprofloxacin is a fluoroquinolone-based inhibitor of bacterial type II DNA 
topoisomerases, including gyrase and topoisomerase IV, which targets a protein-DNA 
intermediate leading to double-stranded DNA breaks (DSB) and stalled replication forks. 34 
 7 
The protein complex, RecBCD processes DSB to ssDNA and stalled replication forks 
inherently expose ssDNA.  This ssDNA substrate, resulting from exposure to ciprofloxacin, 
activates RecA, which in turn induces the SOS response.
 27,35,36
 Similarly, fluoroquinolone 
antibiotics were also found to induce competence for transformation in Streptococcus 
pneumoniae and ciprofloxacin was reported to increase transformation frequency by 
threefold to fourfold in the human pathogen.
14
 
The ability of antibiotic chemotherapy to stimulate SOS and competence extends 
beyond ciprofloxacin and fluoroquinolones to other classes of antibiotics (Table 1.1).  
Among these, β-lactams have been shown to activate SOS expression through a two-
component signaling pathway,
 30
 and aminoglycosides cause an accumulation of 
misfolded proteins that induces competence in S. pneumoniae.
 37
 From this, it is apparent 
that antibiotic-induced stress leads to SOS and competence induction, but that the 
mechanism(s) and signal(s) may differ by antibiotic class and by bacterial species.   
In 2007, a unified mechanism of antibiotic killing was proposed, suggesting that 
all bactericidal antibiotics, regardless of their primary target, cause metabolic stress that 
leads to the production of reactive oxygen species (ROS).
 21,38
 In turn, the highly reactive 
radicals oxidate biomolecules and lead to general cell death.  Subsequent studies reported 
that antibiotic-dependent ROS production oxidizes the guanine nucleotide pool, leading 
to double-strand DNA breaks and death.
 39
 This common mechanism of antibiotic killing 
via ROS production became widely accepted, but was recently refuted by several groups.
 
40-42
 The contradicting studies found that antibiotic treatment did not accelerate the 
formation of hydrogen peroxide nor intracellular free iron,
 42
 essential reactants for the 
production of ROS and that bacteria treated with various antibiotics under aerobic or 
anaerobic conditions had no difference in survival.
 41
 Taken together, this is strong 
 8 
evidence that ROS do not play a role in killing bacteria by antibiotics and that it seems 
unlikely that all bactericidal antibiotics kill by the same mechanism.
 40
 Of course, this 
does not preclude that antibiotics trigger bacterial stress responses, but describes that 
activation of SOS and competence by antibiotics does not involve ROS and that the 
mechanism(s) involved remain elusive.  
 
Table 1.1. 
 
 
 
 
 
 
 
 9 
1.3.2. RecA and the SOS response 
 
The bacterial SOS response is a graded response to DNA damage that initially up-
regulates DNA-excision repair and recombination repair processes, then eventually 
promotes cell-cycle arrest and global mutagenesis if the DNA damage persists.  The 
LexA repressor is a dimeric protein that binds in the promoter region of SOS genes and 
prevents access of RNA polymerase.
 43
 The active RecA nucleoprotein filament (NPF) 
causes LexA to undergo autoproteolytic cleavage, a signaling-like function of RecA that 
is dependent on the formation of an ATP·RecA·ssDNA nucleoprotein filament (NPF).
 
44,45
 The RecA NPF is composed of hundreds to thousands of RecA monomers assembled 
on ssDNA.
 46
 The RecA NPF governs the SOS response, as its activation and ability to 
interact with LexA requires RecA recognition and binding to ssDNA, a rather rare 
substrate that only occurs when DNA damage has occurred or when DNA synthesis is 
interrupted and stalled replication forks are observed.
47
 
The cleavage of LexA sequentially de-represses up to 40 genes involved in DNA 
repair and mutagenic translesion DNA synthesis.
 48-51
  In the early and middle stages of 
the SOS response the bacterium overexpresses proteins, including RecA, involved in 
DNA repair and recombination.  If this attempt at DNA repair is not successful, the late 
stage of the SOS response expresses low-fidelity polymerases that introduce mutations.
 43
  
The mutagenic action of these polymerases creates resistance-conferring mutations.
 
11,13,52-54
  As such, the RecA-mediated SOS response to repair DNA damage, arising in 
the course of antibiotic exposure, facilitates the de novo development and transmission of 
antibiotic resistance genes. 
 While much is now known of RecA and its control of the SOS response, RecA 
 10 
was first identified as “Recombinase A”, the most widely studied and biologically 
important recombinase enzyme in bacteria.
 55
  The activated RecA NPF facilitates 
recombinational repair of damaged DNA.
 56
  In addition, RecA-mediated recombination 
can incorporate foreign genes from exogenous homologous DNA.
 22
  This homologous 
genetic recombination is a frequent source of nucleotide changes that enable bacterial 
evolution including the acquisition of resistance.
54,57-59
 
 In summary, through undetermined mechanism(s), antibiotics induce bacterial 
stress and damage DNA in ways that produce ssDNS and activate RecA.  Once active, 
RecA-mediated processes serve to repair DNA damage while also promoting genomic 
diversification.  Therefore, RecA facilitates accelerated bacterial evolution that occurs in 
response to antibiotic treatment, including the evolution and transmission of antibiotic 
resistance.  
1.3.3. EndA and competence for transformation  
 
 The ability to respond to and repair DNA damage is an essential process required 
by all forms of cellular life.  However, some important pathogens lack the classical SOS 
response as defined by increased mutation after DNA damage and regulation by RecA-
LexA (activator-repressor).  In place of an SOS response, bacteria such as Neisseria 
gonorrhoeae and Streptococcus pneumonia have evolved to be naturally competent for 
DNA transformation.  During transformation, bacteria take up DNA from the 
environment and incorporate it into is genome.
60
  This process is up-regulated when the 
bacteria are under antibiotic-induced stress, and may be exploited for acquisition of 
resistance.
 26
   
 Competence for transformation is an inducible state that arises in response to 
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environmental stressors, including the presence of antibiotics.
 14,61,62
  Like SOS, the 
induction of competence results in the transcription of 105-124 genes that function as the 
regulatory and structural elements associated with transformation.
 63
  Intriguingly, in S. 
pneumoniae, RecA has been shown to be instrumental in activating competence for 
transformation when the bacteria are under antibiotic-induced stress.
 14
  Once competence 
is induced, gene products from the com regulon associate to form a multiprotein complex 
that carries out DNA uptake and transport.
 64
  Within this complex, the surface 
endonuclease EndA degrades the non-transforming strand of DNA (Figure 1.5).
 65
  The 
nuclease activity of EndA is necessary for DNA transport and thus required for efficient 
bacterial transformation in pneumococcus.  It has been demonstrated that S. pneumoniae 
strains with deactivating endA mutations exhibit transformation efficiencies that are less 
than 1% of those of wild-type (wt) strains.
 64,66-68
  Through the activities of EndA, 
bacteria take-up exogenous DNA and eventually integrate it into the chromosome by 
RecA-mediated recombination.
 14
  
 Although some bacteria lack an SOS response, they increase their chances of 
acquiring exogenous DNA through the up-regulation of competence in response to 
antibiotic treatment.
 14
  An important consequence of the transformation-recombination 
process, mediated by EndA and RecA, is genetic diversification and provides another 
example of how antibiotics accelerate evolution and the spread of resistance.  
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Figure 1.4. The transport of DNA during competence for transformation.  Along with 
other Com proteins, EndA is part of the uptake apparatus necessary for DNA transport.  EndA is 
responsible for degrading the non-transforming strand of DNA.      
 
1.4. Other roles of RecA and EndA in bacterial pathogenicity 
1.4.1. RecA 
 
In addition to their roles in accelerated bacterial evolution, RecA and EndA also 
play important roles in establishing infection and in virulence.  As established above, the 
activities of RecA facilitate SOS mutagenesis and genetic recombination, but also are 
reportedly important for disease development following infections by various pathogens.  
E. coli,
 69
 Salmonella enterica,
 70
 Vibrio cholera,
 71
 Helicobacter pylori,
 72
 and S. aureus
73
 
strains that are recA-null have demonstrated significantly attenuated virulence (10
2
-10
6
 
fold).  RecA-mediated recombination has also been shown to play a role in the induction 
of toxin biosynthesis,
 74
 virulence factor production
73
 and the genetic diversification of 
biofilms.
 75
  Therefore, in many diverse bacterial species the activity of RecA plays an 
important role in bacterial pathogenicity. 
1.4.2. EndA 
 
Through transformation-recombination processes, the activity of EndA allows S. 
pneumoniae to diversify its genome and evolve resistance.  EndA activity also allows 
pneumococcal escape of an immune response and promotes the establishment of 
infection.  S. pneumoniae pathogenesis is a complex and dynamic process. The human 
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host continuously deploys an array of innate and acquired immune defenses to prevent 
pneumococci from traversing epithelial barriers.
 76
  Recently, neutrophils have been 
shown to produce neutrophil extracellular traps (NETs) that entrap and kill pathogens in 
the extracellular environment.
 77
  NETs consist of neutrophil DNA as a backbone with 
embedded histones and granule proteins.  In 2006, Beiter and colleagues
78
 showed that 
EndA can degrade the DNA scaffolding of NETs, thereby facilitating pneumococcal 
escape (Figure 1.6).  In mouse models of infection, endA-expressing S. pneumoniae 
strains were able to destroy NETs and disseminate through the mouse, while mutant 
strains deficient in endA remained in the upper respiratory.
 78
  These observations identify 
EndA as a virulence factor that counteracts host-mediated trapping by NETs and 
increases S. pneumoniae pathogenicity.   
 
 
 
Figure 1.5. The structure of NETs and the pathogenic role of EndA in destroying 
NETs.  NETs are extracellular fibrous structures consisting of DNA, histones, and neutrophil 
granular proteins that act to trap and kill bacteria. Endonucleases, like EndA, can degrade the 
DNA backbone of NETs, thus allowing bacterial dissemination and invasive infection
79
. 
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1.5. Intervening in accelerated evolution by small molecule inhibition of 
recombination enzymes 
 
The information presented above establishes that genetic diversification in 
bacteria is accelerated in the presence of antibiotics.  Bacterial genetic diversity 
originates from the SOS response and transformation via competence, processes that are 
regulated by the bacterium and depend on the function of RecA and EndA.  With the 
revelation that accelerated bacterial evolution requires the activity of RecA and EndA, 
there is opportunity to intervene with properly designed inhibitors.  The ability to 
selectively control the activities of RecA and EndA would permit the dissection of the 
stress response pathways (i.e., SOS and competence for transformation), and their 
contributions to accelerated bacterial evolution.  Moreover, small molecule inhibitors of 
RecA and/or EndA would enable a greater understanding of the role of these enzymes in 
bacterial pathogenicity and the development and transmission of antibiotic resistance.  
Finally, by demonstrating that accelerated evolution in bacteria can be attenuated by 
inhibition of RecA and EndA, there is potential that these enzymes will emerge as 
intriguing targets for the discovery of novel drugs to combat antibiotic resistance. 
In the case of RecA, a small molecule inhibitor would enable a greater 
understanding of RecA’s role in the bacterial response to antibiotic chemotherapy.  We 
hypothesize that inhibiting RecA will ultimately prevent the induction of the SOS 
response, impacting both DNA repair and stress-induced mutagenesis pathways that are 
activated as a result of exposure to a wide array of antibiotics.  We propose that an 
inhibitor of RecA activities may lead to one or more of the following outcomes: 
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(1) An inhibitor of RecA may serve as an adjuvant to traditional antibiotic chemotherapy 
by reducing the rate at which resistance genes emerge or are transferred.  Bacteria 
deficient in recA have been shown to have a reduced or nonexistent capacity for 
developing drug resistance.  RecA stimulates the induction of the SOS response, 
promoting de novo mutagenesis and the creation of resistance.  RecA also participates in 
horizontal gene transfer, a process by which resistant genes are shared among bacteria of 
the same and different species.  Inhibition of one or both of these activities will delay or 
completely prevent antibiotic resistance evolution and transmission. 
(2) An inhibitor of RecA may serve as an adjuvant to bactericidal antibiotic 
chemotherapy by potentiating the toxicity of the primary antibiotic.  Bactericidal 
antibiotic exposure induces the recA-controlled SOS response, thereby up-regulating 
DNA repair processes.  It has been shown that RecA-null bacteria are susceptible to 
much lower doses of a wide variety of antibiotics, compared to their wt counterparts
21
.  
Thus, it seems reasonable that a small molecule inhibitor of RecA would synergistically 
enhance the killing effect of currently therapeutically useful antibiotics.  The use of lower 
effective doses of antibiotics may extend the effective life of an antibacterial compound 
or the rescue of shelved compounds.  
 
 Similarly, a small molecule inhibitor of EndA would enable a greater 
understanding of EndA’s activities in pneumococcal accelerated evolution and 
pathogenicity.  As described above, EndA, plays at least two important roles in the 
establishment of pneumococcal infection: (1) EndA is necessary for DNA uptake during 
competence for transformation; and (2) EndA acts as an extracellular nuclease that 
degrades the core component of NETs.  The first activity allows the pathogen genetic 
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flexibility and the easy capacity to acquire resistance, while the second activity affords 
the pneumococcus the ability to establish infection.  Therefore, we propose that an 
inhibitor of EndA activities may lead to one or more of the following outcomes:   
 
 
(1) An inhibitor of EndA may serve as an adjuvant to traditional antibiotic chemotherapy 
by reducing the rate at which resistance genes emerge or are transferred.  Deletion of 
endA diminishes the efficiency of transformation in S. pneumoniae.  Through its role in 
DNA uptake during competence for transformation, EndA contributes to accelerated 
genetic changes that can result in the transfer of antibiotic resistance genes.  Inhibition of 
EndA will decrease or prevent antibiotic resistance development and spread.   
(2) An inhibitor of EndA may serve as an adjuvant to antipneumococcal chemotherapy by 
attenuating infection.  EndA facilitates pneumococcal escape of NETs by degrading the 
DNA scaffold.  Mutant S. pneumoniae strains lacking EndA activity do not destroy NETs 
and show decreased virulence in mouse models of infection.  Thus, it seems reasonable 
that a small molecule inhibitor of EndA would synergistically attenuate infection along 
with a current therapeutic.  A combination strategy with an EndA inhibitor has the 
potential to extend the efficacy of approved drugs and provide better treatment against S. 
pneumoniae.  
1.6. Our strategy to develop small molecule inhibitors of recombination enzymes  
 
Upon antibiotic exposure, genes conferring drug resistance are created by 
increased genetic mutation and/or increased uptake and incorporation of resistance genes 
into the genome.  These processes effectively accelerate the rate at which bacterial 
evolution occurs and novel strategies are required to counter these phenomena.  In this 
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context, the bacterial RecA and EndA proteins have emerged as intriguing targets for the 
small molecule suppression of antibiotic resistance.  Moreover, inhibiting RecA and 
EndA has the potential to potentiate current antibiotics and attenuate pneumococcal 
infection, respectively.  To identify inhibitors of RecA and EndA, we developed high-
throughput screening (HTS) programs that resulted in the discovery of several classes of 
molecules that exert an inhibitory effect on these enzymes. 
The search for inhibitors of any enzyme begins with assays that are capable of 
detecting the influence of a prospective small-molecule modulator on the activity of that 
enzyme.  For our HTS programs, we developed novel biochemical assays capable of 
detecting the inhibition of either RecA or EndA.  The activities of RecA require the 
formation of the RecA NPF that hydrolyzes ATP.  Thus, monitoring ATPase activity can 
be used as a diagnostic for small molecule inhibition of RecA by in vitro screening.  We 
wanted to improved upon previously reported RecA ATPase assays that had sensitivity 
limitations and required high concentrations of enzyme and ATP substrate.
 80-83
  We 
accomplished this by adapting the Transcreener ADP
2
 fluorescence polarization (FP) 
assay from BellBrook Laboratories to detect RecA ATP hydrolysis.  The development 
and optimization of the RecA Transcreener assay for HTS along with initial screening 
results are described in Chapter 1.  The work presented in this chapter has been peer-
reviewed and published in ASSAY and Drug Development Technologies (2012 
Jun;10(3):260-8). 
Following in vitro screening using the RecA Transcreener assay, we identified 
compounds that were active inhibitors of RecA.  These active compounds were further 
assessed for activity, specificity, and mechanism of action in the hit-finding stage of our 
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HTS program.  This stage produces large amounts of data and a thorough analysis of this 
data is discussed in Chapter 3. 
 The hit-finding process identified eight series of compounds with potential for 
further development as RecA inhibitors.  Chapter 4 describes the structural progression of 
one of these series, the styrylquinazolines, and our work towards defining the mode of 
action of styrylquinazolines and select progenitors.  This chapter examines mechanistic 
and physiochemical properties that are important to the identification of RecA inhibitors 
with desired biological activity.   
Finally, we developed a distinct but similar HTS program for the identification of 
EndA inhibitors.  EndA-mediated digestion of double stranded DNA (dsDNA) was 
assessed in biochemical screening by fluorescence changes in the DNA dye ligand, 
PicoGreen.  The novel EndA PicoGreen assay was employed to screen thousands of 
small molecules from both random and directed libraries and measure their ability to 
inhibit EndA nuclease activity.  The development of the EndA PicoGreen assay, 
preliminary screening results and evaluation of active compounds are detailed in Chapter 
5.  We have published the EndA PicoGreen HTS results in Journal of Biomolecular 
Screening 2013 Mar;18(3):247-57 and the virtual screening of EndA, included in 
Appendix I, will be submitted for publication to the  Journal of Medicinal Chemistry.   
The long-range goal of this project is to discover novel small molecules that will 
prevent the de novo development and transmission of antibiotic resistance genes.  The 
projects outlined in this dissertation provide methods for detecting the inhibition of RecA 
and EndA and have resulted in the discovery of several classes of molecules that exert an 
inhibitory effect on RecA or EndA.  Our approach towards understanding and inhibiting 
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accelerated evolution that leads to antibiotic resistance is an intriguing and fresh approach 
to antibacterial discovery.  The development of RecA and EndA inhibitors to combat 
resistant bacterial infections complements traditional antibiotic discovery programs and has 
the potential to extend the clinical utility of existing therapeutics. 
 
Chapter 2 
High-Throughput Screening for RecA Inhibitors Using a Transcreener Adenosine 
5'-O-Diphosphate Assay
1
 
 
2.1. Introduction 
 
New antibacterial strategies will be required to overcome the looming public 
health threat posed by the combination of an increasing prevalence of antibiotic-resistant 
bacterial pathogens with a dwindling pipeline of new antibiotics.
 7,84
 Significant scientific 
and environmental challenges remain in the discovery and development of novel 
mechanism antibiotics.
 85
 One alternative to conventional antibiotic discovery would be 
the development of adjuvants to enhance the outcomes of antibacterial therapy.  Recent 
studies demonstrate that bacterial strains with inactive RecA enzyme are more 
susceptible than wild-type strains to killing by antibacterial agents.
 21,30,54,86
 Moreover, 
loss of RecA function also attenuates the rates of induced mutagenesis and 
intrachromosomal recombination upon antibiotic exposure, thereby slowing the 
development of antibiotic resistance.
 54,86,87
 RecA inactivation also diminishes the 
efficiency of horizontal gene transfer, hindering the acquisition and dissemination of 
antibiotic resistance genes.
 15,88,89
 Given this evidence, we hypothesized that small-
molecule RecA inhibitors could sensitize bacteria to conventional antibiotics and 
attenuate the frequency with which resistance genes develop and are transmitted.
 23
 The 
                                                 
1
 The text of this chapter is taken from a published manuscript that was coauthored with 
Professor Dmitri Kireev, Professor William P. Janzen, and Professor Scott F. Singleton. 
(Peterson, E. J. R.; Janzen, W. P.; Kireev, D.; Singleton, S. F.  Assay and Drug 
Development Technologies 2012, 10 (3), 260-268) 
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discovery of potent and selective RecA inhibitors that modulate the target in living 
bacteria would be an important step in establishing RecA as a druggable target in the 
management of bacterial infectious diseases. 
 RecA’s importance in the bacterial survival of and response to antibacterial 
exposure arise from its cardinal roles in mediating the SOS response and facilitating 
DNA strand exchange.  All RecA activities require the formation of a helical 
homopolymeric filament comprising multiple ATP-bound RecA monomers coating 
single-stranded DNA (ssDNA).
 46
 Once formed, this RecA-DNA filament (RDF) 
hydrolyzes ATP.  Thus, monitoring ATPase activity can be used as a diagnostic for small 
molecule inhibition of RecA by in vitro screening.
 80-83
 These previously reported assay 
technologies had sensitivity limitations, requiring high concentrations of enzyme ([RecA] 
≥ 0.5 M) and substrate ([ATP] ≥ 0.75 mM).  Under such “forcing” conditions, RecA 
exists almost exclusively in an active, DNA-bound conformational state and inhibitors 
selective for this conformation (Figure 2.1A) were primarily identified. 
 The development of a more sensitive screening assay with the ability to detect 
low ATP turnover under reduced RecA and ATP concentrations was desired.  Under such 
“non-forcing” conditions, RecA could sample both its inactive and active conformational 
states, facilitating the identification of additional small molecule inhibitors without bias 
with respect to RecA conformational preference (Figure 2.1B).  Moreover, a reduced 
enzyme concentration would lower the stoichiometric limit on measured IC50 values and 
reduced ATP levels would allow the identification of ATP competitive inhibitors. 
 Assay optimization under these desired conditions represented a challenge 
because the equilibrium constant for RecA self-association during filament assembly and 
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activation is modest and its turnover number for ATP hydrolysis is low (kcat  0.5 s
-1
).  
The robust assessment of RecA’s ATPase activity under such conditions required a 
sensitive detection methodology. 
 The Transcreener ADP2 FP assay from BellBrook Laboratories (Madison, WI) 
is a screening assay kit that allows ADP detection using an ADP-antibody/tracer system 
with fluorescence polarization (FP) readout.  Briefly, the Transcreener ADP
2 
FP assay 
utilizes an antibody that selectively binds ADP to quantify the ADP produced from an 
ATPase reaction.  ADP conjugated to AlexaFluor-633 dye is used as a tracer and the 
amount of tracer that is displaced from the antibody is proportional to the amount of ADP 
generated in the reaction.  This highly sensitive, homogeneous assay technology has been 
used to study protein kinases,
90
lipid kinases,
91
and heat shock proteins,
 92
 Moreover, the 
assays have proven to be suitable for high-throughput screening (HTS).
 93
 In the present 
study, we report the adaptation of the Transcreener ADP
2
 FP assay to detect the ATP 
hydrolysis activity of purified E. coli RecA protein.  We demonstrate the ability of the 
assay technology to be optimized for lower enzyme and ATP concentrations and its use 
in HTS of a diverse collection of drug-like small molecules, leading to the identification 
of novel RecA inhibitor scaffolds. 
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Figure 2.1. Cartoons depicting the inactive RecA monomers and active RecA-DNA 
filament (RDF). (A) Assay conditions, including high concentrations of RecA, DNA, and ATP, 
shift the filament assembly and activation equilibrium such that RecA exists almost exclusively in 
an active, DNAbound conformational state. Inhibitors identified under such forcing conditions 
will be strongly biased toward binders of this conformational state. (B) The desired assay 
conditions include 10-fold lower concentrations of RecA and ATP, and RecA samples both its 
inactive and active conformational states during the assay. Such nonforcing conditions would 
facilitate the identification of additional inhibitors without bias with respect to RecA 
conformational preference as well as ATP competitive inhibitors.  
 
2.2. Assay development and optimization 
 
Previous reaction conditions used for measuring RecA’s ATPase activity required 
relatively high concentrations of RecA and ATP.  To lower enzyme and substrate 
concentrations, we optimized the conditions of the Transcreener ADP
2
 FP assay to our 
desired levels of enzyme and ATP.  We also assessed the robustness, reproducibility, and 
HTS compatibility of the Transcreener assay to ensure its success in screening collections 
of diverse drug-like small molecules for the inhibition of RecA.  
 24 
 An ADP/ATP standard curve was produced (Figure 2.2A), as described in the 
Transcreener ADP
2 
FP
 
assay technical manual.
 94
 The experiment simulates the 
production of ADP during the course of a RecA-catalyzed ATP hydrolysis reaction and 
the expected decrease in FP signal (mP) was observed.  The ATP concentration required 
for half-maximal steady-state velocity, or S0.5 for cooperative enzymes such as RecA,
 95
 
depends on the reaction conditions and published values range from 2.5 to 200 M. 23,96 
In the presence of poly(dT) as the activating DNA, RecA’s ATPase activity was 
measured with initial ATP concentrations from 25 to 100 M.  It was found that 75 M 
was the lowest concentration that resulted in linear (steady-state) kinetics for nearly 40 
min with an acceptable signal-to-background ratio.  Subsequently, under the optimized 
ATPase screening conditions described below, the apparent S0.5 was measured to be 88 
μM (data not shown). Because a substrate concentration equal to or slightly less than the 
KM (S0.5) value in HTS campaigns allows the identification of all types of inhibitors, 
including those that are competitive with substrate,
97
 we selected 75 M as the ATP 
concentration and optimized the other assay parameters. 
 In the presence of 75 M ATP and a saturating concentration of poly(dT) (5 M-
nts), RecA’s ATPase activity increased monotonically with initial RecA concentration 
(data not shown).  A RecA concentration of 30 nM was selected for further experiments 
because this was the lowest RecA concentration to produce approximately linear enzyme 
activity over a reasonable time range and sufficient conversion to achieve an adequate 
signal window.  Optimized conditions included 30 nM RecA, 75 M ATP, and 5 M-nts 
poly(dT).  Employing these conditions, the ADP concentration produced at 37 C was 
measured over time by comparison with an ADP standard curve (Figure 2.2B).  The 
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Transcreener assay demonstrated linear ADP-production kinetics to 40 min and we 
elected to use 30 min as the reaction time to remain comfortably within the assay’s linear 
dynamic range.   
 It is common for small-molecule library samples to be dissolved in DMSO in 
preparation for screening.  Therefore, the effect of DMSO on RecA activity was 
investigated at several different DMSO concentrations, up to 10% (vol/vol) (Figure 
2.2C).  There was no significant reduction in RecA ATPase activity by DMSO up to the 
highest concentration tested and the final DMSO concentration used for screening was 
0.5-1% (vol/vol). 
 To assess the reproducibility of the Transcreener assay, a number of test 384-well 
plates were evaluated for intercolumn, interplate, and interday variability.  Over a span of 
three days, eight replicate assay plates were run under the optimized conditions described 
above and used to compile the mean control signals (Figure 2.3) for Z factor 
calculation
98
.  The maximum activity controls (128 per plate, even columns of a 384-well 
plate) consisted of wells containing RecA, DNA, ATP and 1% DMSO in buffer.  The 
background or inhibited controls (128 per plate, odd columns of a 384-well plate) 
consisted of wells containing RecA, DNA, ATP and 50 mM EDTA in buffer.   The FP 
signal was read at 30 min and the overall quality of the Transcreener assay was assessed 
using the Z factor.  Characteristic of a high-quality assay, the average Z factor was 0.85 
and consistent throughout the validation run. 
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Figure 2.2. Assay optimization with respect to (A) ATP/ADP signal, (B) time and 
enzyme dependence, and (C) DMSO tolerance determined in 384-well format. (A) 
ATP/ADP titration, with a constant adenosine concentration of 75 µM. (B) Reaction time course 
in the () presence or () absence of 30 nM RecA. (C) FP (mP) signal after 30-min RecA 
ATPase reaction in the presence of various amounts of DMSO. The data presented are mean  
standard deviation (SD) of triplicate wells (n = 3).  
 
 
 
    
 
Figure 2.3. Assay validation over multiple plates and multiple days.  Each data point 
represents the mean FP (mP) signal of 128 wells from 3 different experiments on 3 different days 
(2 or 3 plates per experiment); the error bars indicate the SD of each mean value.  The () 
represent the mean values for the background or inhibited controls (50 mM EDTA final) and the 
() represent the mean values for the maximum activity controls (1% DMSO final).  
 
 
 
2.3. Screen design and pilot study of LOPAC library 
 
Using the protocol outlined in Table 1, the Transcreener assay was employed to 
screen the Library of Pharmacologically Active Compounds (LOPAC) as a pilot study.  
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The LOPAC comprises 1,280 biologically active compounds and was assessed in 
triplicate for RecA inhibition at a final compound concentration of 15 M.  The LOPAC 
pilot screen was characterized by an average Z factor of 0.76, and 19 compounds were 
identified with average relative inhibition activities  75% inhibition as an average of 
three replicates (Figure 2.4A).  This active threshold of 75% inhibition represented 6 
standard deviations (SD) above the mean and provided a hit rate of 1.5%.  As shown in 
Figure 2.4B, the pilot screen also demonstrated strong correlation between replicates.  
Analysis of the three replicates revealed five compounds as false positives and an 
estimated false positive rate of 0.4%.   
 The LOPAC was screened previously against RecA using a different ATPase 
assay
16
 under different conditions and 9 of the 19 active compounds were identified as 
RecA inhibitors by both assays.  The high correspondence of the active compounds 
confirmed the Transcreener assay as a reliable method for identifying RecA inhibitors 
from large compound libraries.  Importantly, however, the fact that previously 
unidentified RecA inhibitors were identified using the Transcreener assay substantiated 
our assay design and demonstrated the ability to explore new chemical space for RecA 
inhibitors. 
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Table 2.1. RecA HTS Assay Protocol  
 
Step Parameter  Value  Description 
 
1 Library compound 1 L  10x in R Buffer containing 10% (v/v) DMSO; 15 µM final 
2 Controls   1 L  10x; 1% DMSO and 50 mM EDTA final 
3 RecA    4.5 L  2x in R Buffer; 30 nM final 
4 Pre-incubation  20 min  37 C 
5 ATP & poly(dT)   4.5 L  2x in R buffer; 75 M ATP & 5 M poly(dT) final 
6 Incubation  30 min  37 C 
7 Antibody & tracer 10 L  2x in D Buffer; 37.5 g/mL Ab & 2 nM tracer final 
8 Assay readout  after 30 min EnVision Multilabel Reader using far red FP filter set 
 
Step Notes 
 
1 Multimek transfer to 384-well plates (tip wash 5x with 20 L of dH20) 
2 10% aq DMSO added to columns 1-2; 500 mM EDTA added to columns 23-24 
3 8-tip Multidrop dispense reagent to all wells 
4 plates uncovered in non-shaking incubator 
5 8-tip Multidrop dispense reagent to all wells 
6 plates uncovered in non-shaking incubator 
7 8-tip Multidrop dispense reagent to all wells 
8 plates kept uncovered at 25 C in dark for 30 min until read on multilabel reader using the 
PerkinElmer Cy5 FP dual emission label (620/40 nm excitation filter, 688/45 nm emission filter 
and D658/fp688 dual mirror) 
 
 
 
 
Figure 2.4. Results from the LOPAC pilot screen.  (A) Scatter plot of the mean relative 
inhibition effected by 4,727 compounds from the LOPAC collection against RecA using the 
Transcreener assay. The data presented are mean – SD of triplicate wells (n = 3). (B) Correlation 
plot of the mean relative inhibition from two runs of RecA LOPAC screen with solid line 
indicating perfect 1:1 correlation. 
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2.4. Screening 113,477 compounds for RecA inhibition 
 
Although the pilot screen provided a number of novel inhibitors of RecA, our 
main objective in screening the LOPAC was to validate the Transcreener assay as robust 
and reproducible for the evaluation of additional libraries containing compounds with 
greater potential for development as small-molecule therapeutics.  Towards this end, we 
screened 113,477 compounds from collections at The Center for Integrative Chemical 
Biology and Drug Discovery (CICBDD) at the University of North Carolina at Chapel 
Hill.  Compounds from the 100k Diversity Collection and the Kinase Focus Set were 
screened against RecA in singleton at 15 M from 1 mM DMSO stocks using the 
Transcreener assay.  The Diversity Collection screening results demonstrated a normal 
distribution centered on a mean of 0% inhibition with a SD of 5% (Figure 2.5A).  
Similarly, the Kinase Focus Set screen gave a mean of -0.9% and an SD of 7% (data not 
shown).  Overall, the average Z factor was 0.92 for the 359 analyzed plates (Figure 
2.5B).  A single plate fell below the 0.6 minimum Z factor accepted value and was 
repeated prior to inclusion in data analysis.   
 As summarized in Table 2.2, the 100k Diversity Collection primary HTS resulted 
in a total of 235 compounds with greater than 30% inhibition.  The activity threshold was 
set at 30% inhibition and defined as 6  SD above the mean.  The 30% inhibition cut-off 
was stringent by screening standards and yielded a sufficient number of hits for follow-up 
(0.22% hit rate).  From the 235 initial hit compounds, 78 compounds were selected based 
on their structural representativity
99
 for IC50 determination as described in Materials and 
Methods.  The remaining 157 (of 235) hits were labeled as the “remaining hits” and given 
a second priority in our activity analysis. 
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 We performed a concentration-response study of all the available HTS initial hits 
using the Transcreener assay.  From the representative selection, 77 compounds were 
available in powder stock for evaluation.  The concentration-response measurements 
were performed in triplicate and 66 compounds were characterized by IC50 ≤ 35 M 
(Table 2.2).  The validation rate of the representative selection set was 86%, and nearly 
half of the inhibitors were characterized by IC50 ≤ 10 M.   
 Of the remaining hits, 154 compounds were obtained in powder form and were 
similarly evaluated by IC50 measurement in triplicate.  The concentration-response curves 
allowed 84 compounds to be characterized by IC50 ≤ 35 M (Table 2.2).  The validation 
rate of the remaining hits (55%) was lower than that of the representative selection set, 
but still confirmed over half as validated biochemical RecA inhibitors.  The high 
validation rate of the representative selection set was a result of our structural grouping 
analysis of the HTS results to prioritize the more potent inhibitors.   
 The Kinase Focus Set was collected by the CICBDD and comprised 4,727 kinase-
directed drug-like small molecules not found in the 100k Diversity Collection.  Given 
that both kinases and RecA are ATP-dependent enzymes, a compound library with small 
molecules directed at kinases was screened with hopes it might present compounds active 
against RecA ATPase activity.  The screen yielded 14 compounds with  43% inhibition 
(6  SD above the mean).  The 0.3% hit rate was similar to the Diversity Collection 
screen.  The IC50 determination of the 14 initial hits was performed in duplicate from 
powder stocks and validated 12 compounds as having IC50 ≤ 35 M (Table 2.2). 
 Raw data for three replicates of a validated hit compound is depicted in Figure 
2.6.  There is a clear dose-dependent inhibition of enzyme activity over 6 concentrations 
 31 
tested.  A reproducible IC50 of 5  1 M confirms the robustness and reproducibility of 
the assay. 
 
 
 
 
Figure 2.5. RecA HTS results.  (A) Frequency distribution of the 100K Diversity Collection 
relative inhibition results depicted as a histogram, where the number of compounds in each bin ( 
1% width) is plotted on a linear scale. Inset displays the frequency distribution of bins ( 1% 
width) with greater than 20% inhibition. (B) Z factor analysis of the 359 plates assayed during 
100K Diversity Collection and Kinase Focus Set HTS. 32 wells of inhibited controls (50mM 
EDTA final) and 32 wells of maximum activity controls (1% DMSO final) were used to calculate 
the Z factor. Dashed line indicates Z factor value established as minimum threshold for accepted 
plates to be included in data analysis. 
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Table 2.2. Summary of Successful HTS for RecA Inhibitors 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a
All compounds with  30% inhibition (6xSD above the mean)  
b
Compounds with  30% inhibition and selected based on their scaffold group.  See text for 
selection details. 
c
Compounds with IC50   35 M with visual inspection of curve shape and max % inhibition  
60% 
d
Remaining compounds with  30% inhibition  
e
Compounds with  43% inhibition (6xSD above the mean)  
f
Compounds with IC50   35 M 
 
 
 
 
 
 
Library: 100k Diversity Compound Collection  
Number of compounds tested 108,750 
Overall primary screen hit rate (%) 0.22 
Overall number of hit compounds
a
 235 
Number of hit compounds in representative selection
b
  78 
Validation rate from representative selection (%) 86 
Number of validated
c
 hits from representative selection 66 
Number of remaining hit compounds
d
  157 
Validation rate of remaining hits (%) 64 
Number of validated hits from remaining hits 99 
Overall validation rate (%) 71 
Overall number of validated compounds 165 
Overall number of compounds with IC50   10 M 74 
Library: Kinase Focus Set  
Number of compounds tested 4,727 
Hit rate (%) 0.30 
Number of initial hits
e
 14 
Validation rate (%) 86 
Number of validated
f
 hits 12 
Number of compounds with IC50   10 M 5 
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Figure 2.6. Reproducible concentration–response measurements for validated 
inhibitor UNC10036220 from the 100k Diversity Collection screen. The curve 
representing the mean IC50 value of 5  1 µM was consistent with data from three independent 
runs (circle, square and triangle symbols, respectively). 
 
2.5. Follow-up evaluation of select inhibitors 
 
Further evaluation revealed that many of the inhibitors were active in biological 
assays with live E. coli and were characterized by biochemical mechanisms of inhibition 
that differed from those of known RecA inhibitors.  Of the 165 validated hits from the 
100k Diversity Collection, 35 were active in one or more bacteriological assays for SOS 
activation or fluoroquinolone antibacterial potentiation.  We then selected 15 inhibitors 
that were active in bioassays with live bacteria, were characterized by IC50 values < 10 
M in the Transcreener assay, or both.  For the 15 selected inhibitors, ATPase rates were 
measured as a function of substrate ATP concentration at different inhibitor 
concentrations.  Analysis of resulting velocity-ATP concentration curves unexpectedly 
revealed that none of the compounds exhibited competition with ATP; however, 13 
compounds were noncompetitive inhibitors and 2 were mixed type inhibitors with  > 1. 
100
 Similar characterization of RecA inhibitors identified by previous assays
80-83
 revealed 
only ATP-uncompetitive and DNA-competitive inhibitors, results which were consistent 
 34 
with restricted specificity for the active conformational state of the RecA filament.  
Although we expected some of the tested compounds from the Transcreener assay to 
competitively bind the ATP site, the discovery of inhibitors that target both free RecA 
enzyme and the substrate-bound conformation of RecA confirmed the successful 
identification of RecA inhibitors with varied specificity for RecA conformation.  A full 
accounting of these results will be reported elsewhere. 
 
2.6. Conclusions 
 
RecA facilitates important biological processes that allow bacteria to survive and 
respond to antibacterial exposure.  Because RecA is ubiquitous
101
 and highly 
conserved
102
 among bacteria, but has only distant human homologs,
46,103-107
potent and 
selective RecA inhibitors may serve as novel chemotherapeutic adjuvants to enhance 
conventional antibiotics.  Although we have previously developed biochemical assay 
technologies that allowed target-based screening to identify RecA inhibitors, the prior 
assay conditions restricted both the available conformational state of RecA and the 
inhibitor mechanistic types that could be explored.  A major conclusion of this work is 
that the Transcreener ADP
2
 FP assay method could be adapted for a robust and 
reproducible HTS (Z′ = 0.92) of 113,477 small molecules for inhibition of RecA ATPase 
activity.  The sensitivity of the Transcreener ADP
2 
FP technology allowed the enzyme 
and substrate concentrations to be reduced by more than an order of magnitude.  From the 
compounds identified as active in the primary HTS assay, 246 compounds were 
evaluated in concentration-response format and 79 inhibitors characterized by IC50 ≤ 10 
M were identified.  Importantly, the evaluation of a subset of the inhibitors revealed 35 
that were active in one or more assays with live E. coli and that a number of new 
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mechanistic types and selectivities for RecA conformational states were identified.  These 
novel RecA inhibitors represent a variety of chemotypes and 33 unique scaffold groups 
(group size > 1) that will serve as synthetically tractable hit series for medicinal 
chemistry efforts aimed at optimizing biochemical and bacteriological inhibition of RecA 
activities. 
 In part, the continued search for new RecA inhibitors is motivated by the 
increasingly urgent public health threat posed by antibiotic-resistant pathogens. It is now 
clear that the use and misuse of antibiotics has played major roles in the selection and 
spread of resistant pathogens. The exposure of bacteria to antibacterial compounds results 
in the selection of resistant variants that ultimately dominate the population.  Importantly, 
however, recent studies suggest that bacteria are not merely passively subjected to natural 
selection but can actively promote genetic diversification. The origins of genetic variation 
include local changes in the DNA sequence (mutation), intrachromosomal shuffling of 
DNA sequences (recombination), and the acquisition of DNA sequences from other 
organisms (horizontal gene transfer).  Induced mutagenesis in response to antibiotic 
exposure dramatically accelerates bacterial mutation.
 11,52-54
 Likewise, recombination 
plays a major role in bacterial evolution,
12,54,58,59
and may be a more frequent source of 
nucleotide changes in E. coli than de novo mutation.
 57
 Finally, horizontal gene transfer is 
an important source of genetic diversity in bacteria.
15,22,108,109
  
 The genetic diversification processes described above are regulated by the 
bacterium and depend on the function of select proteins and enzymes, including RecA.  
Indeed, RecA has multiple functions that contribute to induced mutation, intragenomic 
recombination, and horizontal gene transfer, including induction of the SOS response by 
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stimulating autocleavage of the LexA repressor, activation of error-prone DNA 
polymerase V by stimulating autocleavage of UmuD, and facilitation of homologous 
genetic recombination.  The biochemical dependency of these phenomena on RecA 
activities suggests that potent, selective RecA inhibitors could be developed to attenuate 
the development, acquisition and dissemination of resistance, affording an opportunity to 
inhibit evolutionary processes and enhance antibacterial chemotherapy.  Current 
experiments are underway to evaluate the inhibitors of RecA’s DNA-dependent ATPase 
activity in bacteriological assays. 
 
2.7. Materials and Methods 
 
2.7.1 Materials and equipments 
 
The Transcreener ADP
2
 FP assay kit (cat. No. 3010-10K) was purchased from 
BellBrook Labs.  Poly(dT) single-stranded DNA was purchased from The Midland 
Certified Reagent Company (Midland, TX).  RecA was purified and stored as previously 
described.
46
 Unless otherwise stated, all other reagents used for buffers and assays were 
purchased from Fisher Scientific International (Ipswich, MA). 
 
2.7.2 LOPAC compounds collection 
 
The Library of Pharmacologically Active Compounds (LOPAC) was purchased 
from Sigma-Aldrich as 10-mM stocks in DMSO.  The library was previously prepared as 
1-L samples in 384-well V-bottom polypropylene microplates (Greiner, Monroe, NC), 
sealed by a ALPS 3000 microplate heat sealer (Thermo Fisher Scientific, Hudson, NH) 
and stored at -20 C.  On the day of use, the compounds were thawed and diluted to 150 
M (10x final concentration) in R Buffer (Reaction Buffer:  25 mM Tris-HOAc, 10 mM 
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Mg (OAc)2, 1 mM DTT, 5% glycerol, and 0.01% TritonX-100) over 2 steps using a 
Thermo Scientific Multidrop Combi Reagent Dispenser (Waltham, MA) and Multimek 
NSX-1536 assay workstation system fitted with a 384-well head (Nanoscreen, 
Charleston, SC).  Finally, 1 L of this stock was spotted into the wells of a 384-well 
black PerkinElmer Proxiplate (Waltham, MA) for assay use, as described below. 
 
2.7.3. 100k Diversity screening compound collection 
 
The 100k Diversity Collection of screening compounds was developed by 
structural chemists from St. Jude and the CICBDD.  Compounds were selected based on 
structural diversity at the Murcko scaffold level.
 99
 Essentially, a compound’s Murcko 
scaffold includes contiguous ring systems plus chains that link two or more rings.  For 
Murcko scaffolds with more than 20 compounds, 20 compounds were randomly selected 
for that scaffold in order to maximize the diversity of scaffolds in the Diversity 
Collection.  Compounds were also filtered to eliminate reactive function groups (REOS 
score > -2)
110and include compounds that obey the “rule of five” 111 with slight deviations 
in order to permit slightly larger and more lipophilic compounds.  Based on the above 
selection process, a set of 100k compounds was chosen and purchased from Enamine Ltd 
(Kiev, Ukraine) in powder stock.  At random, around 5% of the collection was examined 
by LC/MS for identity and purity confirmation.  The compound collection plates were 
prepared by resuspending the powder stock to 1 mM in DMSO in barcoded glass vials 
with sonication using a Covaris S2 (Covaris, Woburn, MA).  Compounds were plated at 
1 mM in 100% DMSO in 384-well V-bottom polypropylene microplates using a Tecan 
Genesis 200 (Münnedorf, Switzerland).  A Multimek spotted 1 L of the 1 mM 
compounds into 384-well V-bottom polypropylene microplates and plates were heat 
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sealed and stored at -20 ºC.  During screening, these previously prepared plates were 
thawed and diluted to 150 M by a single addition of R Buffer, and 1 L of this stock 
was spotted into the wells of a 384-well Proxiplate. 
 
2.7.4. Kinase focus set 
 
The Kinase Focus Set was designed by the CICBDD based upon a combination of 
kinase pharmacophore-based searching and selection from vendor kinase directed sets.  
The 4,727 compounds chosen for the Kinase Focus Set were distinct from any in the 
Diversity Collection and all were “rule of five” compliant. 111 The Kinase Focus Set was 
acquired from several vendors in powder stock.  Compound and assay plates were 
prepared the same as the 100k Diversity Collection. 
 
2.7.5. Transcreener assay 
 
The assay was performed by using a Multidrop dispenser to add 1 L of 10% 
DMSO in the left two columns (columns 1, 2) for the positive control reactions.  In the 
right two columns (columns 23, 24), 1 L of 500 mM EDTA was spotted for the negative 
control reactions. Assay reactions were carried out directly in the Proxiplate wells 
containing 1 L compounds or controls.  The reaction volume in each well was 10 L, 
and final concentrations of compound and DMSO were 15 M and 0.1%, respectively.  A 
2x solution of RecA was prepared in R Buffer.  To all wells of the assay plates, 4.5 L of 
the 2x RecA in R Buffer was added using a Multidrop dispenser.  RecA was allowed to 
pre-incubate with compounds and controls for 20 min in a 37 C air incubator.  
Following pre-incubation, a 2x cocktail of ATP and poly(dT) ssDNA in R Buffer was 
added at a volume of 4.5 L to each well.  Immediately upon addition of the 
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ATP/poly(dT) mixture, assay plates were again transferred to the 37 C air incubator and 
the reaction was allowed to proceed for 30 min.  After 30 min, the plates were removed 
and quenched by adding 10 L of 2x Transcreener D Buffer (Detection Buffer:  50 mM 
HEPES, pH 7.5, 400 mM NaCl, 0.02% Brij-35, 20 mM EDTA) with 4 nM Transcreener 
AlexaFluor 633 ADP tracer, and 75 g/ml ADP2 antibody.  To ensure uniformity of 
results, no more than 20 plates were processed at a time during screening and plates were 
incubated at ambient temperature for 30 min prior to reading on an EnVision Multilabel 
Reader (PerkinElmer) using far red FP filter set.  
 Compounds for dose-response runs were resuspended to 10 mM in DMSO in 
barcoded glass vials.  The representative selection hits and Kinase Focus Set hits were 
sonicated using the Covaris S2 and plated as 3-fold dilutions over 10 points using the 
Tecan in 384-well V-bottom polypropylene microplates.  The remaining hits were 
resuspended and placed in a sonicating water bath if needed for solubility.  The dose-
response curves of the remaining hits were prepared as 3-fold dilutions over 10 points 
using a multi-channel pipette.  Compound titration series of all hits for IC50 evaluation 
were spotted at 1 L by a Multimek instrument into 384-well V-bottom microplates and 
diluted 20-fold in R Buffer using a Multidrop dispenser.  The diluted titrations were then 
spotted at 1 L into 384-well black Proxiplates in duplicate or triplicate, and reagents 
were added to initiate the assay as described above.  The final top concentration of dose-
response curves was 50 M compound (0.5% DMSO).  
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2.7.6. Data analysis 
 
The fluorescence polarization (FP) of the ADP tracer was measured using the far 
red FP filter set from PerkinElmer (optimized Cy5 FP Dual Emission label, 620/40 nm 
excitation filter, 688/45 nm emission filter and D658/fp688 dual mirror) with the G factor 
set at 0.64.  The emission values were calculated to a milli-polarization (mP) signal using 
the following fluorescence polarization fit sequence: 
 
                                      (1) 
 
where G is the G-factor (0.64), S is the emission filter parallel to the excitation filter and 
P is the emission filter perpendicular to the excitation filter.  
 Screening data was processed using ScreenAble software (Screenable Solutions, 
Chapel Hill, NC).  The percent inhibition was determined on a plate-to-plate basis by 
comparing the calculated mP value per compound well with the plate-averaged control 
wells (n=32 for each control), using the following relationship: 
 
                           (2) 
 
 
where mP is the compound well mP signal, and inh and max are the plate-averages of the 
minimum signal (maximum ATPase activity, 1% DMSO added) and maximum signal 
(inhibited, 50 mM EDTA added) controls, respectively.  
 The Z factor was calculated for each assay plate to assess the quality and 
robustness of the HTS.  The Z factor was determined using the following formula: 
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                                                   (3) 
 
 
where max and min are standard deviations in respective plate maximum and minimum 
signal controls, and max and min are the plate-averages of the respective controls, as 
defined above.  
 Compound IC50 values were calculated by first converting the mP signal to 
percent inhibition with respect to on-plate controls and then fitting the percent inhibition 
values to curve equations using ScreenAble or Prism (GraphPad Software, San Diego, 
CA).  The IC50 values of the representative selection hits and Kinase Focus Set hits were 
calculated using ScreenAble with a 3- or 4-parameter curve fit.  The remaining hits were 
analyzed in Prism using a one-site specific binding with Hill slope and Bmin. 
 
2.7.7. Selection of representative active compounds 
 
The representative compounds were selected according to the following 
procedure. First, all 235 actives from the 100k Diversity Collection were grouped into 
compact clusters of similar compounds. More specifically, the similarity between any 
two compounds within a cluster was at least 65% according to the Tanimoto metrics with 
ECFP4 fingerprints (Pipeline Pilot, ver 7.5; Accelrys Software, Inc.; 2009). The 
clustering procedure revealed 22 clusters (of 3 to 10 compounds) and 92 singletons; i.e., 
compounds that did not have any structural analogs amongst the 235 hits. Despite being 
outliers among the hits, most of 92 singletons had numerous structural analogs that did 
not show any activity in the Transcreener assay. These compounds were assigned a lower 
priority because of a high risk of them being either false positives or intractable hits. 
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Finally, the first priority representative subset of 78 compounds consisted of 3 
compounds per cluster that showed the highest response in the primary high-throughput 
screening (i.e., 66 actives) and 12 “true” singletons (i.e., hits that did not have any 
structural analogs neither among other hits nor among the inactive compounds).
 
Chapter 3 
Comprehensive Data Analysis for RecA Inhibitor Program 
 
3.1. Introduction 
 
 With the development of robotics, liquid handling devices, sensitive detectors and 
data processing software, high-throughput screening (HTS) entered the drug discovery 
process nearly 20 years ago.
 112
  HTS is now widely used, both in industry and academia, 
to identify compounds that modulate a particular biomolecular pathway on a massive 
trial-and-error basis.  As such, HTS serves as a primary means to identify chemical 
compounds for further characterization as to activity, specificity, and mechanism of 
action, all as part of the process to generate hits (compounds with confirmed and desired 
activity).  These numerous tests produce data sets that are large in both quantity and 
complexity.  Therefore, a thorough and sophisticated analysis of the data is also crucial in 
a rational path to hit generation in a drug discovery program.       
Only through a rational integration of chemistry, HTS data, and multiple sources 
of follow-up data, can correct interpretations and full exploitation of the data be achieved.  
Towards this end, we developed a computational framework that combines chemical 
structure with RecA high-throughput screening data and information from follow-up 
microbiological activity assays.  From the integration and analysis of these data sets we 
describe: (1) the attrition of compounds from full library HTS to identification of 
tractable hit series, (2) the relationship between enzyme inhibition and in vitro bacterial 
 44 
activity, and (3) the identification of prospective RecA inhibitors in previously ignored 
structural classes.  Our analysis provides insight into the success of HTS in RecA 
inhibitor discovery and addresses the utility of current chemical libraries in antimicrobial 
discovery.  Most importantly, our results will help inform and improve decision-making 
in future RecA inhibitor discovery work.  
3.2. Evaluation of compound attrition in hit generation stage 
 
 The typical stages in the modern, target-directed drug discovery and development 
process are hit generation, lead generation, and lead optimization (Figure 3.1).
 113
  The 
main goal of this process is to select only the drug candidates that are worthy of 
expensive and time-consuming clinical testing.  Failures in late-stages are costly and 
therefore elimination of flawed compounds at the early-stages of discovery is crucial.  In 
particular, the hit generation stage, which involves the HTS of large chemical libraries 
and follow-up activity assays, experiences the largest attrition of any pre-clinical stage.  
Using our database of integrated data, we discuss the compound attrition of our RecA 
inhibitor program in the hit generation stage and compare our results to average HTS hit 
generation programs. 
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Figure 3.1. Stages in the drug discovery process.  Typical steps in the drug discovery 
process, which ensure only drug candidates with high potential are advanced to the next phase.  
As each stage is more costly and time consuming, it is important to eliminate unfavorable 
compounds early in the process.
 113  
 
 
 As summarized in Figure 3.2, the RecA inhibitor discovery program screened 
113,477 compounds from collections at CICBDD.
 114
 Compounds from the 100k 
Diversity Collection and the Kinase Focus Set were screened against RecA in singleton at 
15 µM using the Transcreener ADP
2 
FP assay.  Primary HTS resulted in a total of 251 
“active” compounds with  30% inhibition or  6SD above the mean.  The “active” hit 
rate of the RecA primary screen calculates to 0.2%, which is marginally low.  From 
primary screen reports, the average range of hit rates is from 0.1-2%,
115
 and while 0.2% 
is within this range it is on the low end.  Regardless, 251 compounds provided a 
sufficient number of “actives” for further investigation.   
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Figure 3.2. Compound attrition during hit generation stage of RecA inhibitor 
discovery program.  Altogether, in primary screening, 133,447 compounds were assessed 
from library collections at CICBDD.  From this, 251 “actives” were identified (0.2% hit rate), of 
which 246 were selected to retest in dose-response format and 183 passed as “IC50 actives” (74% 
confirmation rate).  Of these, 150 were available as dry powder compounds and retested.  
Inspection of compound structures and activity data selected 117 “confirmed actives” for 
continued follow-up.  In secondary and functional assays, 26 compounds showed favorable 
activity and were established as “hits,” with 8 “hit series” identified for further development.   
 
 
Cluster analysis and inspection of the 251 “active” structures eliminated 5 
compounds based on structural features expected to impart toxicity, chemical reactivity 
or extremely poor pharmacokinetic properties.  The remaining 246 compounds were 
tested in dose-response and prioritized based on their IC50 curves.  Our guidelines for 
prioritization based on IC50 curves required IC50  30 M, max % inhibition  60% and 
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visual inspection of curve shape.  Of the 246 compounds tested in dose-response, 183 
compounds were selected as “IC50 actives,” a 74% confirmation rate.  Fresh powder 
stocks were available for 150 of the 183 “IC50 actives” and were retested in dose-
response.  Further inspection of structures eliminated compounds with established assay 
interference
116
 or promiscuity
117
 and prioritized 117 “confirmed actives” for continued 
follow-up.   
Further evaluation revealed that 28 compounds were active in biological assays 
with live bacteria.  Of the 117 “confirmed actives”, 23 compounds potentiated 
fluoroquinolone activity in bacteriological assays and 4 compounds inhibited SOS 
reporter gene activity in E. coli (see subsections 3.6.3 and 3.6.4 of Materials & Methods 
for assay details and activity selection).  There was just one compound (UNC10001584) 
with activity in both assays for fluoroquinolone potentiation and SOS activation in E. 
coli.   
The HTS of large chemical libraries (~150,000 compounds), typically result in 5-
30 “hits” with only 2% of “actives” becoming “hits.”3 If 26 microbiologically active 
compounds are considered to be “hits,” then the RecA Transcreener HTS assay yielded 
results consistent with the expected number of “hits” and 11% of our “actives” became 
“hits.”  We further reviewed our “hits” and selected 8 “hit series” for further 
development, based on activity, ease of synthesis, and SAR indications.  This resulted in 
3% of our “actives” considered as “hits series,” which is very close to the typical 2%.  
With this analysis, we find our RecA HTS and hit generation results to be close to the 
average.  However, further development of our “hit series” has been rather unsuccessful 
and prompted us to review the results from our secondary assays and search for 
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additional “hit series” that might have been overlooked.  These topics will be discussed in 
the following sections of Chapter 3.  
 
3.3. Relationship between enzyme inhibition and in vitro bacterial activity  
 
 In Chapters 1 and 2, we presented evidence that RecA-controlled processes are 
responsible for accelerated evolution in response to antibiotic chemotherapy.  It has been 
shown that bacteria having loss-of-function mutations in the recA gene are exquisitely 
sensitive to antibiotic treatment.
 54,118
 Therefore, a small molecule inhibitor of RecA 
could act synergistically with currently prescribed antibiotics, greatly enhancing their 
potency.  Moreover, a small molecule capable of inhibiting RecA would impact RecA-
mediated processes, which include activation of the SOS response.  We have detailed the 
RecA HTS results and the identification of “confirmed actives” as potential RecA 
inhibitors.  The next critical step in the hit generation process for RecA inhibitors 
involves characterizing the effect of “confirmed actives” in live bacteria.  This testing 
determines the “hit series” for further development and provides preliminary evaluation 
of therapeutic potential.  After demonstrating in vitro inhibition of RecA, a number of 
compounds were tested in bacterial assays for antibiotic potentiation and SOS activation.  
In this section, we will discuss the results of these experiments and examine the potential 
relationship between enzyme inhibition and in vitro bacterial activity. 
3.3.1 Antibiotic potentiation 
 
The first step in evaluating the microbiological activities of RecA inhibitors was 
to determine whether they potentiate the killing of bacteria by antibiotics.  It has been 
demonstrated that inactivation of recA increases the activity of many antimicrobials, as 
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measured by a decrease in the minimum inhibitory concentration (MIC) of antibiotics in 
recA-deficient E. coli.
 54
 Moreover, Singleton group’s internal results have demonstrated 
that RecA inhibitors enhance bacterial killing by many classes of antibiotics (unpublished 
results).  Therefore, to prioritize “hit series” for further development, compounds were 
tested for their potentiation of bacterial killing following treatment with a sub-inhibitory 
dose of antibiotic.   
The abilities of all “confirmed active” compounds to potentiate bacteria killing by 
ciprofloxacin (fluoroquinolone class) were measured in MG1655 (wt) and D22 (lpxC101) 
strains of E. coli and in S. aureus (wt strain ISP794).  The mutant D22 (lpxC101) E. coli 
strain has outer membrane hyperpermeability and provides valuable information about 
membrane penetration, which could be a factor limiting bacteriological activity for a 
given inhibitor.  Similarly, the testing of RecA inhibitors in S. aureus (a gram-positive 
bacteria) may identify RecA inhibitors that exhibit low activity in E. coli (a gram-
negative bacteria) but possess more potent activity in S. aureus.  This minimizes the risk 
of overlooking useful RecA inhibitors and those that are amenable for chemical 
manipulation to improve activity. 
RecA inhibitors were assessed for their ability to enhance the killing of the 
bacterial strains above by sub-inhibitory doses of ciprofloxacin.  Viability was assessed 
using Oxygen Biosensor System assay, which produces a fluorescence signal in a given 
well when oxygen-utilizing viable cells are present.  Mid-log cultures of bacteria were 
plated into wells with ciprofloxacin at 0.5x MIC concentration and 100 M RecA 
inhibitor.   After overnight culture, the emission of each well was recorded and 
normalized to either the control wells with ciprofloxacin alone to calculate the 
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“potentiation factor” or to the control wells without ciprofloxacin to calculate the 
“lethality factor.”  The “potentiation factor” results were comparatively analyzed with 
data for bacteria exposed to RecA inhibitor alone, the “lethality factor.”  Compounds that 
specifically inhibit RecA should not affect cell viability in the absence of antibiotic and 
were seen as unattractive in our RecA inhibitor program (lethality factor ≥ 0.5).  
Complete analysis of the results found that 30 of the 150 compounds tested, all 
“actives” obtained in fresh powder, potentiated ciprofloxacin in either E. coli strains. 
However, 23 out of the 30 compounds produced cell death by compound alone, resulting 
in 2 compounds with ciprofloxacin potentiation in MG1655 (wt) E. coli and 5 compounds 
with ciprofloxacin potentiation in D22 (lpxC101) E. coli (Figure 3.3), with no overlap.  
Additionally, there were 14 compounds that potentiated ciprofloxacin in S. aureus, but all 
had high lethality factors as well (Figure 3.3).  We also tested a limited number of 
compounds (83 compounds) for gentamicin (aminoglycoside class of antibiotic) 
potentiation in S. aureus and a sizeable 29 compounds displayed potentiation, with 17 
having no compound alone lethality.  It would be informative to assess the remainder of 
compounds to determine whether this high rate of gentamicin potentiation is real or an 
artifact of the subset that was tested.   
In total, 23 compounds displayed antibiotic potentiation, and only one compound 
displayed potentiation of ciprofloxacin in MG1655 (wt) E. coli and also for gentamicin in 
ISP1794 S. aureus (compound UNC10000435).  The next step in evaluating the 
biological activity of compound UNC10000435 and the other 22 compounds that 
potentiated antibiotics is to determine whether their activities depend on RecA function.  
This could be done by testing RecA inhibitors at various concentrations in an rdgB 
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variant of E. coli.  The rdgB mutants require RecA for recombination repair of DSB (rdg 
= Rec-dependent growth)
119
and selective inhibitors of RecA should be lethal to the 
rdgB strain.  
In general, a low percentage (15%) of the compounds tested had any antibiotic 
potentiation.  All of the 150 compounds tested had IC50s  30 M in the RecA 
Transcreener assay, but only 23 potentiated antibiotics in bacteria.  These results 
demonstrate a weak relationship between enzyme inhibition and microbiological activity 
and limit the progress towards hit generation.  
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Figure 3.3. Compounds potentiate ciprofloxacin bacterial killing.  D22 (lpxC101) E. 
coli, MG1655 (wt) E. coli and ISP794 S. aureus were treated with ciprofloxacin at ½ MIC 
concentration and 100 µM of compound.  The cells were plated into wells of O2 Biosensor 
System and cultured overnight at 37 C.  In a platereader, wells were then read for fluorescence 
intensity, and values were either normalized to the condition with no inhibitor and no 
ciprofloxacin to calculate the “lethality factor” (grey filled bars, left) or to the condition of 
ciprofloxacin alone to calculate the “potentiation factor” (open bars, right).  It was determined 
that 5 compounds potentiate ciprofloxacin in at least one bacterial strain, meeting the criteria that 
potentiation factor is ≥ 0.5 and lethality factor is ≤ 0.5.  
 
3.3.2 Inhibition of SOS activation  
 
 
Given the importance of RecA and the SOS response in accelerating the evolution 
of antibiotic resistance, a therapeutically significant RecA inhibitor would need to 
demonstrate reduction in SOS activation.  Members of the Singleton lab developed an in 
vitro assay to measure RecA-mediated activation of SOS response genes in E. coli.  The 
assay utilizes the Beta-Glo system120 and E. coli having a sulAp-lacZ reporter gene 
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(strain DM4000).
 121
  The induction of SOS was measured in compound-treated DM4000 
bacteria exposed to sub-inhibitory dose of ciprofloxacin and comparatively analyzed to 
cells not exposed to ciprofloxacin.  The following control E. coli strains were also used: 
SS1492, which is a DM4000 mutant that expresses a hyperactive RecA that constitutively 
activates LexA autoproeolysis (and constitutively produces -galactosidase), even in the 
absence of DNA damage; and JC19098, which is a DM4000 mutant that expresses an 
uncleavable LexA repressor variant and is therefore not inducible (no -galactosidase 
expression is induced) (Figure 3.4).  
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Figure 3.4. -galactosidase strains used in SOS activation assay.  The DM4000 E. coli 
strain carries a recombinant sulAp-lacZ SOS reporter gene on it chromosome and produces an 
increase in -galactosidase activity when treated with sub-inhibitory dose of ciprofloxacin (+ 
CIP). The SS1492 strain is a DM4000 mutant that expresses a hyperactive RecA that 
constitutively activates LexA autoproteolysis and constitutively produces -galactosidase 
activity, even in the absence of ciprofloxacin (- CIP).  The JC19098 strain is a DM4000 mutant 
that expresses an uncleavable LexA repressor variant and no -galactosidase activity is induced, 
even in the presence of ciprofloxacin.  
 
As detailed in the subsection above, 23 compounds demonstrated antibiotic 
potentiation and 20 of these compounds were tested for their inhibition of SOS activation 
by ciprofloxacin.  Analysis of the results identified 4 compounds (Figure 3.5) that 
exhibited a dose-dependent inhibition of SOS activity in the DM4000 strain (EC50 values 
≤ 30 µM), with no adverse -galactosidase activity in the control strains over the 
compound concentration range (example EC50 curve in Figure 3.6).  Importantly, the 
SOS inhibition of these compounds was only significant in the presence of polymixin B 
nonapeptide (PMBN), a small-molecule that increases E. coli membrane permeability.  
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This signifies that these compounds have difficulty penetrating the outer membrane and 
might have limited utility without chemical manipulation.  It should also be noted that the 
relative potency of in vitro RecA inhibition (RecA IC50) does not correlate with the 
microbiological SOS inhibitory activity (SOS EC50) (Figure 3.5).  Again, this disparity is 
likely to due to the capacity of the compounds to reach and accumulate in the cytosol, 
which is necessary for inhibition of a cytosolic target such as RecA.  It is clear that RecA 
inhibitors identified by in vitro screening most often have limited activity in bacteria.   
 
 
 
Figure 3.5. Compounds inhibitory activity in E. coli SOS gene reporter assay.  Four 
compounds were able to inhibit RecA-mediated activation of core SOS response gene, sulA, 
based on the following criteria of triplicate data in the presence of ciprofloxacin and PMBN, (1) 
DM4000 strain EC50 values ≤ 30 µM, (2) calculated % max values ≥ 60%, and (3) SS1492 control 
strain % max values ≤ 50%.  Compound UNC10001584 (boxed) also had a ciprofloxacin 
potentiation factor of 0.7 (n=1) and lethality factor of 0.1 (n=1) in D22 (lpxC101) strain of E.coli.  
The RecA IC50 values were calculated from duplicate or triplicate dose-response experiments 
using the Transcreener assay. 
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Figure 3.6. Dose-dependent inhibition of SOS activation by RecA inhibitior 
UN10001584.  The black () symbols and corresponding curve represent the mean SOS EC50 
value of 2 ± 0.08 µM in DM4000 E. coli from triplicate data.  Compound UNC10001584 did not 
influence SOS expression in the control strains SS1492 and JC19098.   
 
3.4. Identification of prospective compounds for follow-up as “hits” for RecA 
inhibition 
 
 In 2010 Synereca Pharmaceuticals selected 8 higher-priority hit series based on 
the limited data set available at the time and the company’s finite resources.  Synereca 
licensed the “hit series” from UNC for subsequent development and commercialization.  
Now, armed with this comprehensive analysis of hit discovery stage data, we wanted to 
examine the possibility that there were other “hit series” worthy of consideration. 
 Of particular interest are the four compounds with inhibition in the SOS activation 
assay.  Two of the compounds belong to “hit series” already licensed by Synereca, while 
the other two compounds (UNC10104668 and UNC10104551) have not been 
investigated further and are structurally similar, both containing a 5-alkylidene-4-
thiazolidinone (“rhodanine-like”) moiety (Figure 3.7).  Such rhodanine-containing 
compounds are considered pan assay interference compounds (PAINS),
 116
 classes of 
compounds known to be identified as actives in screens with many different targets and 
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thought of as poor choices for drug development.  Whereas some authors characterize 
rhodanines as assay-interfering compounds that broadly interact with a plethora of targets 
and are therefore practically useless in drug discovery,
 116
 others see these moieties as 
“privileged scaffolds”, 122,123 the idea that more biologically active compounds are built 
around some structures than others.   
In a systematic study of 163 rhodanine-containing compounds, it was determined 
that their promiscuity is not related to nonspecific properties such as aggregation or 
reactivity, but rather to electronic and hydrogen-bonding properties that can be 
elucidated.
 122
 This suggests that the biomolecular binding properties of rhodanine-
containing compounds can be exploited in a useful way.  Indeed, rhodanine-containing 
compounds are in clinical use for the treatment of type II diabetes (Avandia, 
GlaxoSmithKline)
 124
 and in 2012 approved for the treatment of metastatic castration-
resistant prostate cancer (Xtandi, Medivation).
 125
  Given this and the compelling activity 
of the compounds UNC10104668 and UNC10104551, they may be worth further 
investigation as RecA inhibitors.  
 
 
 
Figure 3.7. 5-Alkylidene-4-thiazolidinone series as prospective compounds for 
follow-up.  UNC10104551 and UNC10104668 demonstrated significant inhibition of SOS 
reporter gene assay and are structurally similar, containing a rhodanine-like moiety. 
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3.5. Conclusion 
 
 The success of a hit generation program is largely dependent on two main aspects: 
(1) the quality of the biology of HTS and follow-up assays and (2) the size, diversity, and 
physiochemical quality of compounds in the screening collection.
 126
 In terms of assay 
quality, the superb screening statistics and high validate rate (see Chapter 2) support the 
conclusion that the Transcreener assay was an appropriate HTS assay for RecA.  
However, as discussed above, there was a weak correlation between biochemical enzyme 
inhibition and activity in microbiological assay.  This lack of relationship could also be 
attributed to the physiochemical limitations of the compounds that were discovered by 
HTS and more a problem with the quality of the screening collection. 
 There is a general problem in the quality and diversity of chemical libraries, 
especially for screening against bacterial targets.
 127
 In a review of GlaxoSmithKline’s 
(GSK) extensive antibacterial screening program, the screening of chemical libraries for 
inhibitors of specific bacterial enzymes resulted in inhibitors that either had no 
microbiological activity or with activity that was not proven to be due to inhibition of the 
desired target enzyme.
 85
 The authors and others concluded that GSK’s antibacterial 
programs failed primarily because of the limitations in synthetic chemical libraries used 
for screening.  A recent presentation suggested that Pfizer’s antibacterial programs had 
similar outcomes.
 128
 Most chemical libraries were developed for drug discovery in other 
therapeutic areas and these libraries appear non-optimal for drug discovery in bacteria.
 129
 
In general, activity in bacteria requires compounds that are less hydrophobic and smaller 
in size than those found in typical screening libraries.
 129
 These differences arise from 
factors unique to bacteria that must be considered, including bacterial cell penetration, 
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metabolism, elimination, and bacterial resistance.   
In order to improve the potential for finding RecA inhibitors and much-needed 
antibacterials, chemical collections must be better designed with molecules that can enter 
and stay active in bacteria.  Moreover, all chemical libraries could be improved by 
removal of interfering and potentially toxic compounds and by increasing diversity. 
3.6. Materials and Methods 
 
 
3.6.1 Materials and equipment 
 
 The integration of data was processed in Vortex (Dotmatics Ltd, Bishops 
Stortford, UK).  For antibiotic potentiation, MG1655 and D22 (lpxC101) E. coli strains 
were purchased from the E. coli Genetic Stock Center (Yale University, New Haven, 
CT).  ISP794 S. aureus strain was a generous gift from Professor David Hooper, Harvard 
Medical School.  Oxygen Biosensor System (OBS) plates were purchased from BD 
Biosciences (San Jose, CA).  In the SOS activation assay DM4000 E. coli containing 
sulA-lacZ reporter gene and control E. coli strains, JC19098 and SS1492, were obtained 
from Steve Sandler’s lab at the University of Massachusetts at Amherst.  Beta-Glo 
reagent was purchased from Promega (Madison, WI).  All other reagents were purchased 
from Sigma-Aldrich (St. Louis, MO) at the highest level of purity possible.    
 
3.6.2. Transcreener Assay 
 
Materials and methods for Transcreener assay were reported in Chapter 2.   
 
 
 
 
 
 
 
 60 
3.6.3. Antibiotic potentiation assay 
 
 For each strain of bacteria, cells were grown in sterile LB overnight with shaking 
in incubator at 37
 C.  Cell were subcultures into fresh LB broth and then grown to mid-
log phase (OD600 = 0.5-0.8).  Cells were dilute into 25 mL LB broth to final OD600 = 0.01 
and 190 L was added to all wells of an OBS plate.  Antibiotic (ciprofloxacin or 
gentamicin) was added (5 L) to wells (not to control wells) at 40x the final 
concentration, which was 0.5x MIC.  The 0.5x MIC for ciprofloxacin in MG1655 (wt) 
was used at 12.5 ng/mL, in D22 (lpxC101) was 6.25 ng/mL and in ISP794 was 50 ng/mL.  
The 0.5x MIC for gentamicin in ISP794 was used at 0.5 µg/mL.  Finally, 5 L of 
compound in DMSO (or DMSO alone) was added at 40x the final concentration (100 
µM).  The plate was sealed with breathable membrane and incubated in the shaker at 37
 
C for 20 hours.  After 20 hours, fluorescence was measured using a POLARstar Optima 
platereader.  The normalized “potentiation factor” was calculated by the following 
equation: 
           Potentiation factor = Ftot / Ftot(Ctrl-Inh)                                        (1) 
 
 
where Ftot is the total fluorescence value per well and Ftot(Ctrl-Inh) is the total 
fluorescence value in control wells having no inhibitor.  Similarly, the normalized 
“lethality factor” was calculated by the following equation: 
 
                                       Lethality factor = Ftot / Ftot(Ctrl-Inh,-Abx)                                   (2) 
 
 
where Ftot is the total fluorescence value per well and Ftot(Ctrl-Inh) is the total 
fluorescence value in control wells having no inhibitor and no antibiotic.  A value near 
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unity indicates the cells in that well remained viable, while a value near zero indicates a 
loss in viability. 
 
3.6.4. SOS gene reporter assay 
 
Single colonies from DM4000 E. coli streaked onto agar plates were selected and 
used to inoculate liquid LB cultures.  LB cultures were incubated at 37° C overnight in a 
shaker.  The overnight E. coli LB cultures were inoculated 1:100 into fresh LB and 
incubated at 37° C in a shaker until the OD600 > 0.5.  The E. coli subcultures were diluted 
into fresh LB to an OD600 = 0.01 and Polymyxin B nonapeptide (PMBN) was added to a 
final concentration of 4 μg/mL.  The diluted cells (48 μL) were added to the wells of a 
96-well plate containing 1 μL of inhibitor (50x final concentration) in DMSO or DMSO 
as a control.  Plates were incubated at room temperature for 20 minutes on a shaker.  In 
the next step, 1 μL of ciprofloxacin (50x final concentration of 20 ng/mL) in DMSO or 
DMSO as a control was added to the wells. Final assay volume was 50 μL and plates 
were incubated at 37° C on the shaker for 1 hour.  After 1 hour, 2 μL of 8 mg/mL 
lysozyme (final concentration ~0.3 mg/mL) was added to the wells.  Plates were 
incubated at room temperature for 20 minutes on a shaker.  Finally, 30 μL of Beta-Glo 
reagent was added to the wells and the plate was incubated at room temperature on the 
shaker for 40 min.  Luminescence was measured on a POLARstar Optima plate reader 
using the gain adjustment feature of the instrument set to 40% of maximum on a well 
with the highest luminescence values on the plate. 
 
Chapter 4 
Evaluating Modes of RecA Inhibition by Structurally Related Class of Small 
Molecules 
 
4.1. Introduction 
  
There is a critical need to prevent the evolution and transmission of resistance to 
antibacterial drugs.  Drug resistance thwarts the treatment of bacterial infectious diseases 
and new strategies are needed to counter bacterial mechanisms that lead to drug 
resistance.  In this context, RecA is a potential target because its activities accelerate the 
evolution and spread of antibiotic resistance.  With properly designed inhibitors of RecA, 
we can better understand its role in evolutionary processes and develop drugs to stop the 
emergence and spread of antibiotic resistance.   
We have developed rational high-throughput screening programs to discover 
small-molecule inhibitors of RecA.  High-throughput screening (HTS) is a useful method 
for the identification of novel classes of small molecule inhibitors.  From our HTS 
efforts, a number of compound classes containing unique scaffolds were identified.  
These compound classes were studied in further detail and distinguished 
“styrylquinazolines” as exhibiting desirable biochemical and microbiological activities.  
In this chpater, we discuss the medicinal chemistry path that led to the 2-styryl-4-
aminoquinazolines as a prospective hit series.  We also present our work towards 
defining the mode of action of 2-styryl-4-aminoquinazolines, and specifically, their 
undesirable interactions with DNA and formation of colloidal aggregates.  Evaluation of 
 63 
mechanistic and physiochemical properties are important to the identification of RecA 
inhibitors with desired biological activity. 
4.2. Structural modifications aimed at selective inhibition of RecA 
 
 RecA’s activities are carried out through two distinct protein conformational 
states, A and P, which are required for induction of SOS mutagenesis and genetic 
recombination, respectively.  Both A- and P-state activities of RecA require the formation 
of a RecA-DNA filament (RDF) that hydrolyzes ATP.  Thus, monitoring ATPase activity 
can be used as to identify small molecule inhibitors of RecA by HTS.   
A series of RecA inhibitors containing a diarylpyrimidine core moiety (e.g., 
screening active in Figure 4.1) was previously identified by our laboratory in 
collaboration with BRITE at NCCU.
 82,83
  Remarkably, biochemical and bacteriological 
evaluation of nearly 80 congeners led us to conclude that they are functionally selective 
inhibitors of the P-state of E. coli RecA.
 130
  A compound with a diarylpyrimidine core 
(BRITE-345133 in Figure 4.1) was the most potent of the compound series, and inhibits 
RecA’s ATP hydrolysis activity with IC50 = 5 μM.  Evaluation of potency using kinetic 
ATPase assays revealed that BRITE-345133 is uncompetitive with ATP binding, 
suggesting that it binds to the RDF complex (i.e., the A-state).  Interestingly, BRITE-
345133 completely prevented DNA strand exchange (at 25 μM), suggesting that BRITE-
345133 also binds the P-state conformation of RecA.   
Microbiological assays revealed that BRITE-345133 elicited a dose-dependent 
partial attenuation of SOS induction by ciprofloxacin and potentiated killing by 
ciprofloxacin, ampicillin, kanamycin, chloramphenicol and mitomycin C.  Potentiation of 
ciprofloxacin killing was particularly robust and BRITE-345133 reduced the MIC for 
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ciprofloxacin by a factor of four.  Importantly, BRITE-345133 did not influence killing 
of ΔrecA E. coli by any of the antibacterial agents.  Finally, BRITE-345133 abrogated the 
ability of chloramphenicol-resistant E. coli to emerge after overnight or longer growth in 
supplemented minimal media.
 131
  
Microarray-based gene expression analysis (carried out in the lab of James J. 
Collins at Boston University) confirmed that BRITE-345133 did not fully prevent RecA-
mediated activation of core SOS response genes but did prevent RecA from participating 
in DNA repair.  
Taken together, the biochemical, microbiological and gene expression results are 
fully consistent with the mechanistic hypothesis that BRITE-345133 binds to both A- and 
P-states of RecA, but permits some SOS induction while selectively inhibiting the 
recombinational activities (DNA strand exchange and repair) associated with the P-state 
of RecA. 
Unfortunately, BRITE-345133 and its congeners possess characteristics that limit 
their immediate utility.  First, the physicochemical properties result in poor solubility and 
bacterial permeability.  Second, BRITE-345133 demonstrates off-target effects in 
microbial and gene expression assays.  Finally, preliminary human cell-based assays with 
several compounds reveal frank cytotoxicity likely associated with this chemotype. To 
overcome these challenges, we undertook two activities: computational modeling to 
identify new chemotypes and analog development to produce an improved hit series. 
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Figure 4.1. Structural modifications toward improved hit series.  Analogs of screening 
actives were made, including BRITE-345133, which exhibited desirable biochemical and in vitro 
bacteriological properties; however, were toxic in mammalian cell culture.  Computational 
methods led to identification of styrylquinolines and ST072510 which are well tolerated in 
animals but have known associations with DNA.  Finally, styrylquinazolines have an extra 
nitrogen in the quinolone ring that decreases the electron density of the heteroaromatic core and 
reduces DNA binding.  Moreover, a nitro or other electron-withdrawing group off the quinazoline 
right seems to decrease interactions with DNA.  
 
In collaboration with the UNC Molecular Modeling Lab (Prof. Alex Tropsha, Dr. 
Denis Fourches, Melody Luo) we undertook ligand-based pharmacophore and QSAR 
modeling to predict alternative scaffolds and chemotypes that could be evaluated as RecA 
inhibitors.
 132
 To date, no structural data for a RecA-inhibitor complex have been 
generated.  However, ligand-based computational approaches
133,134
 allowed robust 
models to be built and prospective inhibitor structures to be predicted.  Some chemotypes 
were similar enough to commercially available compounds to allow immediate testing.  
To evaluate whether commercially available analogs were bona fide inhibitors of E. coli 
RecA, 11 were purchased and assessed for a variety of inhibitory activities.  Of these 
commercial analogs, a 2-styryl-4-aminoquinoline (ST072510 in Figure 4.1) inhibited 
RecA’s DNA-dependent ATPase activity with IC50 = 5.3 ± 0.4 μM.   The styrylquinoline 
core of ST072510 is distinct from the diarylpyrimidine core of BRITE-345133.  
Moreover, ST072510 was found to attenuate ciprofloxacin-induced activation of SOS 
and potentiate killing by ciprofloxacin in E. coli.  Searches of literature and chemical 
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databases for information about ST072510 revealed that the compound is available as an 
over-the-counter antimalarial drug in Russia.
 135
 It was demonstrated that ST072510 is 
tolerated in animals
135,136
and suggests that styrylquinolines have improved drug-like 
properties relative to diarylpyrimidines.   
Further interest in ST072510 was generated by the fact that other aminoquinoline 
compounds have long been known to be pharmacologically active.
 137,138
 In particular, 
quinacrine and chloroquine (Figure 4.2) were shown to have antibacterial effects
139,140
 
and, remarkably, were demonstrated to prevent the emergence of resistant bacterial 
strains when quinacrine was combined with an antibiotic.
 20,141
  
Despite the promising activities of ST072510 and reported efficacy of 
aminoquinoline analogs in bacteria, studies also indicate these compounds have strong 
interactions with DNA.
 142-144
 Consistent with these reports, we found that the RecA 
inhibitory activity of ST072510 was dependent on the structure of DNA used in the RecA 
ATPase assay.  When using 174 phage DNA, which has a mix of single-stranded and 
double-helical regions,
145
the IC50 of ST072510 was 6-fold lower than when using 
poly(dT) single-stranded DNA (ssDNA).  This lower IC50 in the presence of 174 DNA 
compared to poly(dT) presents a possible mechanism where styrylquinolines are binding 
DNA, which was also demonstrated in studies with aminoquinoline analogs. 
In a paper investigating the interaction of DNA with styrylquinolines, thermal 
denaturation studies observed a stabilization of dsDNA in the presence of 
styrylquinolines, but significantly less in the presence of styrylquinazoline derivatives 
(similar to R103888 in Figure 4.1).
 144
 From this, we hypothesized that the simple 
addition of an extra nitrogen into the quinolone ring decreases the electron density and 
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thereby reduces intercalative interaction and binding to DNA.
 144
 We tested some of these 
styrylquinazoline compounds and observed activity consistent with a RecA inhibitor 
acting on target in bacteria.  They are also believed to be well tolerated in vivo based on 
rat toxicity studies done with compounds that feature a similar polycylic heteroaromatic 
core.  For example, Pfizer CP-31398 is tolerated at doses exceeding 80 mg/kg in mice.
 146
 
Given this, we have prioritized the styrylquinazolines as a RecA inhibitor hit series for 
further development.  In the next sections, we examine the mode(s) of inhibition of RecA 
by 2-styryl-4-aminoquinazolines and focus on the results of four compounds, R103888, 
R103918, R101680 and R890855, compared to BRITE-345133 and ST072510.  
Specifically, we investigate their interaction with DNA and propensity to form colloidal 
aggregates.      
 
 
 
Figure 4.2. Pharmacologically active aminoquinolines.  The aminoquinolines, 
chloroquine and quinacrine, are structurally related to styrylquinoline compound, ST072510.  
Quinacrine and chloroquine were approved as antimalarials in the 1930s and 1940s, respectively.  
ST027510 is approved and manufactured as aminochinol in Russia as an antimalarial.  All three 
compounds have previously reported activity against bacteria and observed DNA interactions.  
ST072510 and quinacrine inhibited RecA in vitro while chloroquine did not.      
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4.3. Investigating DNA binding by styrylquinazolines and progenitor compounds 
using thermal denaturation  
 
 Medicinal chemistry efforts identified the 2-styryl-4-aminoquinazoline hit series 
for further development.  The 2-styryl-4-aminoquinazolines inhibited RecA with 
potencies as low as 10 µM and demonstrated attenuation of SOS induction and 
ciprofloxacin potentiated killing in E. coli.  To advance this series towards in vivo testing 
we characterized the interaction of 2-styryl-4-aminoquinazolines with DNA.  A 
compound that binds DNA can appear as a RecA inhibitor by sequestering the DNA and 
preventing it from activating RecA’s ATPase activity.  We can examine this off-target 
activity of small molecules by exploring DNA binding directly in thermal denaturation 
studies. 
 Small molecules can associate with DNA through combinations of electrostatic, 
hydrogen-bonding, or hydrophobic interactions that are dependent or independent on the 
base sequence.  The interaction of small molecule ligands with DNA can effect the helix-
coil transition in the DNA, leading to either increases or decreases in the thermal 
denaturation temperature.
 147
 Most ligands stabilize the double-stranded form of DNA 
(dsDNA) and cause an increase in the thermal denaturation temperature.  However, a 
ligand association with ssDNA is possible and has destabilization effects that are 
accompanied by a decrease in the melting point.
 148
 Given this, we employed thermal 
denaturation studies to determine 2-styryl-4-aminoquinazoline and progenitor compounds 
(Figure 4.3) associations with DNA, and whether they bind more strongly to ss- or ds-
DNA. 
 The thermal denaturation studies of poly(dA)poly(dT) were carried out using UV 
spectroscopy at 260 nm (Prof. Dev Arya, Clemson University).  In the absence of 
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compound, poly(dA)poly(dT) melting curves had a clear inflection at Tm = 63 C 
(Figure 4.4A).  Duplex stabilization was found to be dependent on the concentration of 
ST072510, shifting the Tm from 63 C to 71 C at 2.5 rbd (ratio of base pair/drug).  The 
duplex stabilization of ST027510 was similar to previous thermal denaturation studies 
using calf thymus DNA, which reported a Tm = 10 C.
 144
 However, CP-31398 did not 
stabilize duplex DNA as expected from studies investigating its interaction with DNA. 
(ref)  These studies indicate CP-31398 might require a protein-DNA complex for 
interaction, which might explain our thermal denaturation results (Tm = 1 C) in the 
absence of protein.   
For the unknown compounds, duplex stabilization was found to be dependent on 
the concentration of BRITE-345133, but not for the 2-styryl-4-aminoquinazolines, 
R890855 and R103888.  Figure 4.5 shows that as the molar ratios of ligand decreased 
from 10 to 2.5 rbd, the melting point increased by 12 C for BRITE-345133 (Figure 
4.4B).  The transition temperatures of the 2-styryl-4-aminoquinazolines (R890855, 
R103888) were virtually unaffected.  
  A qualitative analysis of the thermal denaturation results suggests that BRITE-
345133 and ST072510 interact with dsDNA, while the styrylquinazolines do not.  None 
of the compounds seem to associate with ssDNA.  While interpreting the results, 
additional factors, such as number of binding sites and cooperativity of ligand binding, 
may need to be considered and complicate ligand DNA binding inferences.  Most 
important, thermal denaturation studies occur at high temperatures.  This allows for the 
possibility that ligands that did not shift melting temperatures at high temperatures (>60 
C) may have interactions with DNA (ssDNA or dsDNA) at lower temperatures.  Our 
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biochemical ATPase assays are performed at 37 C, making conclusions drawn from 
thermal denaturation studies less than fully applicable.  To explore ligand DNA binding 
directly at lower temperatures (room temperature, 22-25 C) we used an equilibrium 
dialysis assay and will discuss in the next section.      
 
 
 
Figure 4.3. Ligands assayed for thermal denaturation shift.  Left panel: We investigated 
the ability of one diarylpyridine (BRITE-345133), one styrylquinoline (ST072510) and three 
styrylquinazolines (CP-31398, R890855, R103888) to shift the thermal melting temperature.   
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Figure 4.4. UV melting profiles of poly(dT)poly(dA) in the absence of ligand (A) 
and in the presence of BRITE-345133 at base pair to drug ratio (rbd) of 2.5 (B) at a 
rate of 1 °C/min.  Without ligand, the poly(dA)poly(dT) melting temperature was Tm = 63 C.  
In the presence of BRITE-345133 at rbd of 2.5, the poly(dA)poly(dT) melting temperature was 
Tm = 75 C.  Buffer conditions; 100 mM NaCl, 10 mM S.C., 0.5 mM EDTA, pH 6.8. 
 
 
 
 
Figure 4.5. UV melting temperatures of dsDNA in the presence of ligands. UV 
melting temperatures at 260 nm without ligand (Tm C) and Tm values at 10, 7.5, 5 and 2.5 ratio 
of base pairs to drug (rbd) for ligands in Figure 4.4.  Without ligand, the poly(dA)poly(dT) 
melting temperature was Tm = 63 C.  The melting transitions were unaffected by CP-31398, 
R890855 and R103888.  The diarylpyridine and styrylquinoline stabilized the duplex form of 
DNA at decreasing rbd.  The uncertainty of Tm is  1 C.  Buffer conditions; 100 mM NaCl, 10 
mM S.C., 0.5 mM EDTA, pH 6.8.  
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4.4. Evaluation of direct ligand DNA interactions using competition dialysis 
 
 Small molecules that bind to a particular DNA structure are challenges to our 
program to find selective inhibitors of RecA.  To explore the possibility of compounds 
directly binding to DNA, we employed thermal denaturation studies monitored by UV 
absorbance.  However, melting curves can be complex and have attributes that make the 
analysis and interpretation of data difficult.  As an alternative, we used a competition 
dialysis assay for detecting ligand binding to a variety of nucleic acid structures.  
 The competition dialysis assay is based on the thermodynamic principle of 
equilibrium dialysis.
 149
 In brief, the approach places a DNA structure inside a 
semipermeable dialysis membrane with pore sizes that allow small molecules to pass 
through but which retain the DNA structure.  The dialysis unit is then placed into a 
dialysate solution containing small molecule ligand.  At equilibrium, the chemical 
potential of the free ligand must be equal inside and outside the dialysis unit, and any 
excess ligand on the DNA structure side of the membrane is attributed to binding of the 
DNA structure.  The competition dialysis assay was adapted to evaluate structure 
selective ligand binding to DNA.
 150-152
 This was accomplished by using mini dialysis 
units containing a variety of DNA structures at identical concentrations and collectively 
suspending the units in the dialysate solution (Figure 4.6).  The details of the competition 
dialysis assay protocol are described in the materials and methods section.  
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 Figure 4.6. Schematic diagram of the competition dialysis experiment.  Multiple 
disposable dialysis units, each containing 0.2 mL of a 75 µM solution of one of the DNA 
structures listed in Table 4.5, are placed in a beaker containing 500 mL of a 10 µM ligand 
solution. The system is allowed to equilibrate for at least 48-72 h with continuous shaking. The 
amount of ligand bound to each DNA structure is determined spectrophotometrically as described 
in Materials and Methods.   
 
 Using the competition dialysis assay, we first assessed a standard intercalator, 
ethidium bromide, for binding to the nucleic acid structures found in Table 4.1.  
Ethidium bromide has been extensively studied
150,153
 and served as a provisional test of 
our assay set up.  As expected, we found ethidium bromide had a strong preference for 
dsDNA (calf thymus Cbound = 24.7  0.5 µM, poly(dA)poly(dT) Cbound = 10.0  0.5 µM, 
poly(dT) Cbound = 0.6  0.5 µM, and poly(dA) Cbound = 1.0  0.5 µM).   
Once satisfied with the pilot study, we tested BRITE-345133, ST072510, 
R890855, R101680, R103888, and R103918 in the competition dialysis assay.  After 
equilibration period, DNA samples were transferred from dialysis unit to microcentrifuge 
tubes and the solutions were adjusted to a final concentration of 1% (w/v) sodium 
dodecyl sufate (SDS).   The free ligand concentration (Cf) and total ligand concentration 
within each dialysis unit (Ct) were determined spectrophotometrically, using wavelength 
maxima and extinction coefficients appropriate for each ligand (Table 4.2).  Finally, the 
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total amount of bound ligand was determined by Cb = Ct – Cf.  Inspection of bar graphs 
compared ligand binding to the four different DNA structures.  Figure 4.7A shows that 
ST072510 binds to duplex DNA structures as expected
144
 and as observed in our DNA 
thermal denaturation studies.  Similarly, BRITE-345133 also supported Tm data by 
displaying a preference for duplex DNA structures, with more binding to 
poly(dA)poly(dT) (Figure 4.7B).  R101680 was not tested for duplex stabilization by 
Tm shift and showed appreciable binding to poly(dA)poly(dT) by competition dialysis, 
but not to the standard duplex calf thymus DNA (Figure 4.7D) and was the only 
styrylquinazoline to significantly bind a duplex DNA structure.  The remaining 
styrylquinazolines, R103888 (no Tm observed) and R103918 (not tested in Tm), 
showed no binding to any of the DNA structures (Figure 4.7E and F).  R890855 was the 
only compound assayed that bound to single-stranded forms, in this case poly(dT) 
(Figure 4.7C).  In thermal denaturation studies, R890855 did not destabilize duplex 
DNA as would be measured by a decrease in Tm in the presence of R890855.  This result 
is the only discrepancy between  Tm data and competition dialysis results and could 
indicate that R890855 interaction with ssDNA is effected by temperature.  In summary, 
the styrylquinazolines do not interact with dsDNA as observed by thermal denaturation 
and competition dialysis, while the styrylquinazoline, R890855, has an affinity for 
poly(dT) at room temperature.    
It must be noted that the masses pre- and post-assay balance accounting (Figure. 
4.6 box insets) of most styrylquinazolines did not balance, with a considerable amount of 
ligand lost to glass and plastic surface binding during the equilibration period.  This has 
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previously been seen competition dialysis studies
152
 but did not preclude interpreting 
ligand DNA binding preferences in these cases.  
 
Table 4.1. Nucleic acid samples used in competition dialysis experiments 
 
  
 
 
Table 4.2. Absorption maxima and extinction coefficients of styrylquinazolines and 
progenitor compounds 
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Figure 4.7 Results obtained by the competition dialysis method for styrylquinazoline 
and progenitor compounds. The amount of ligand bound to each DNA structure is shown as 
a bar graph. The molecular structure of each compound is shown beside each graph.  The box 
inset represents the mass balance and calculates the amount of ligand that was recovered after 
dialysis.   
  
4.5. Evaluation of small molecule colloidal aggregate formation 
 
 The apparent loss of material observed for the styrylquinazolines could result 
from a number of phenomena, including surface binding, insolubility, aggregation, or any 
combination of the three.  In the past few years it has become clear that many small 
molecules, when diluted from DMSO solutions into aqueous buffer, can self-associate 
and form aggregates.
 154
 These aggregates form at micromolar concentrations and are 
often several hundred nanometers in diameter, although invisible to the naked eye.  Once 
formed, they can nonspecifically sequester enzymes and intractably inhibit their activity 
(Figure 4.8).  In addition, other aggregate-induced artifacts may arise depending on assay 
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specifics (e.g., sequestration of DNA structures, aggregates binding to surfaces).  In the 
end, compounds with aggregative tendencies should be avoided for drug discovery as 
they lead to established problems of specificity and developability.
155
 
 In recent years, efforts in both academia and industry have resulted in methods to 
detect compound aggregation.  These methods include inhibition of a model enzyme (-
lactamase)
 117
 and counter-screens based on the detergent-sensitivity of aggregate-based 
inhibition.
 156
 There are also methods to directly detect aggregate particles and here we 
describe our efforts to directly detect aggregation of styrylquinazoline compounds using 
light scattering and Transmission Electron Microscopy (TEM). 
 There are two types of light scattering measurements, namely static light 
scattering (SLS) and dynamic light scattering (DLS), that can be used to measure 
properties of particles in solution.
 157
 SLS measures the time-average intensity of light 
scattered from molecules in a solution, where the intensity of scattered light is 
proportional to both the concentration and size of particles in the solution.  Therefore, 
SLS can be used to detect when there is a change in particle size caused by, for example, 
aggregation.  The other commonly used form of light scattering, DLS, measures time-
dependent fluctuations in the intensity of scattered light, which occur because particles 
are undergoing random Brownian motion in the solution.  From these measurements the 
hydrodynamic radius and size distribution of the particles can be derived.  The DLS 
technique is extremely sensitive for measuring large aggregates in solution, but does not 
prove reliable when the particle size distribution is very wide.  Moreover, foreign 
particles and aggregates that form non-spherical particles also complicate DLS analyses.  
Therefore, we elected an approach that uses SLS to measure the compound critical 
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aggregation concentration (CAC).
 158
 The CAC represents a threshold above which 
compound aggregation occurs and provides an estimation of the maximum obtainable 
concentration of monomers in a given aqueous solution.   
 The light scattering-based method to detect compound CACs was preformed by 
preparing serial dilutions of compounds in 20 mM HEPES buffer (pH 7.0).  Dilutions 
were placed in wells of a 96-well plate and measured for static light scattering in a 
commercial light scattering plate reader (DynaPro™, Wyatt Technology Corporation, 
Santa Barbara, CA).  Using this method, we performed preliminary experiments with a 
known aggregator (tetroaiodophenolpthalein, TIPT) and a structurally similar compound 
that does not assemble into aggregates (8-anilino-1-naphthalene-sulfonic acid, ANS).
 159
  
Satisfied with the results of the control study, we tested the styrylquinazolines with 
solutions that were or were not filtered using a 0.2 µm syringe filter.  The SLS intensities 
collected from compound solutions at different concentrations are shown in Figure 4.9 
and the estimated CAC values are tabulated in Table 4.3.  All the compounds tested had 
aggregation behavior in light scattering with compounds R103888, R101680, R890855 
and R103918 all having CAC values ≤ 6 µM (Figure 4.9A-D).  Compounds R103888 
(Figure 4.9A) and R101680 (Figure 4.9B) showed typical aggregator plots and the 
removal of all particles when filtered.  On the other hand, particles were still present after 
filtration for compounds R890855 (Figure 4.9C) and R103918 (Figure 4.9D).  This 
unexpected behavior may be explained by the passage of very small particles through the 
filter that then formed larger particles in the dilution wells.  The detectable particles 
reformed at the same concentration as non-filtered samples for R890855 but needed a 
higher concentration for R103918.  Filtration removed all particles for compound 
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ST072510 (Figure 4.10E) and the CAC value (25 µM) was significantly higher than the 
other styrylquinazolines.  The higher CAC may explain the complete mass-balance 
observed for ST072510 in the equilibrium dialysis experiments.  The light scattering plot 
for BRITE-345133 (Figure 4.9F) was rather atypical; the parabolic shape increased at 
concentrations ≥ 0.8 µM and then decreased at concentrations ≥ 10 µM, returning to 
background light scattering intensities.  We cannot explain this curious activity, but 
fundamental problems with BRITE-345133 solubility were noted above. 
 We used transmission electron microscopy (TEM) to visualize the particles 
formed by styrylquinazoline compounds.  Consistent with results from light scattering 
experiments, solutions of these compounds formed aggregates in the same buffer (Figure 
4.10A-D).  Individual spherical aggregates are up to 100 nm in diameter and associate 
into larger branched structures.  Direct physical detection using light scattering collection 
and TEM observation suggests that styrylquinazolines form aggregates in solution at 
concentrations similar to their IC50 values against RecA.   
  
 
 
Figure 4.8. Proposed mechanism of nonspecific inhibition by compound aggregates. 
Some small molecules (i.e. tetroaiodophenolpthalein, TIPT, shown above) form particles from 50 
to over 400 nm in diameter, and these particles sequester target enzymes, thereby inhibiting 
them.
154 
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Figure 4.9. Results obtained by static light scattering (SLS) for styrylquinazolines 
and progenitor compounds . The SLS intensities collected from filtered and non-filtered 
compounds in 20 mM HEPES at different concentrations.  The critical aggregation concentration 
(CAC) was estimated as the highest concentration point exhibiting SLS intensity 
indistinguishable from the solvent background (dashed lines).  The data plotted is the average of 3 
trials and the standard error is indicated.  The molecular structure of each compound is shown 
beside each graph.     
 
 
Table 4.3. CAC by static light scattering for styrylquinazolines and progenitor 
compounds 
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Figure 4.10. Transmission electron micrographs of styrylquinazolines.  Compounds in 
20 mM HEPES buffer (pH 7.4): (A) R890855, (B) R101680, (C) BRITE-345133, (D) R103918, 
(E) R103888. Bars represent 100 nm. 
 
4.6. Conclusions 
 
 The preliminary identification of progenitor compounds from high-throughput 
screening led to the discovery of a core styrylquinazoline structure with improved RecA 
inhibitory activity.  The styrylquinazolines inhibit RecA’s ATPase activity with potencies 
as low as 10 µM, attenuate ciprofloxacin-mediated induction of SOS and potentiate 
killing by ciprofloxacin in E. coli.  Moreover, we have demonstrated that 
styrylquinazolines do not associate with dsDNA, which is an improved property over 
their structural predecessor, the styrylquinolines.  One analog, R890855, associated with 
ssDNA in the equilibrium dialysis experiment but was not corroborated by dsDNA 
destabilization in thermal melting curves.  By all accounts, the styrylquinazolines 
exhibited desirable biochemical and bacteriological properties and are believed to be well 
tolerated in animals.  However, a demonstration of aggregation may diminish the 
enthusiasm for developmen of the styrylquinazolines.  Measurements of critical 
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aggregation concentrations (CACs) suggest that styrylquinazolines form particles in 
aqueous solution below 6 µM.  Transmission electron microscopy also revealed 
characteristic aggregation of the styrylquinazolines in solution.  The aggregative behavior 
of the styrylquinazolines merits further study, but does not categorically preclude further 
development of the compound class; it is known that several approved cancer drugs form 
stable colloids in biochemical buffers and cell culture media
160
.                 
4.7. Materials and methods  
 
 
4.7.1 Materials and equipment 
 
Calf thymus DNA was purchased from Sigma Chemical Co. (St. Louis, MO) and 
were sonicated and chloroform/phenol extracted as previously reported
161
.  Poly(dA), 
poly(dT), and poly(dA)poly(dT) were purchased from Midland Certified Reagents 
(Midland, TX) and used without further purification.  All other reagents were purchased 
from Sigma-Aldrich (St. Louis, MO) at the highest level of purity possible.  DNA and 
ligand concentration were determined spectrophotometrically using a Cary 100 Bio 
UV/Vis spectrophotometer.  Ultraviolet DNA melting curves were determined using a 
Cary UV/visible spectrophotometer (Varian, Inc., Palo Alto, CA), equipped with a 
thermoelectric temperature controller.  Confocal static light scattering measurements 
were carried out with a commercial light scattering plate reader (DynaPro™, Wyatt 
Technology Corporation) equipped with an 830 nm diode laser.  TEM images were 
obtained with a LEO EM910 transmission electron microscope.   
 
4.7.2. UV Thermal Denaturation Studies 
  
UV melting studies were performed in Singleton lab and in the laboratory of Prof. 
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Dev Arya at Clemson University.  A buffer consisting of 100 mM NaCl, 10 mM S.C., 0.5 
mM EDTA, pH 6.8 was used for melting experiments.  For all experiments, RNA 
concentrations were 20 µM/base pair.  Solutions of DNA (final concentration of 20 µM) 
were prepared by direct mixing with aliquots from a ligand stock solution, followed by 
incubation for 12 h at 24 °C to ensure equilibration. Samples were heated at a rate of 
1 °C/min, while the absorbance was being continuously monitored at 260 nm. Plotting 
and analysis was performed with the software supplied by Cary UV/Vis Kinetics 
Program and GraphPad Prism for plotting and analysis. 
 
4.7.3. Competition Dialysis Assay 
 
Concentrations of nucleic acid samples were determined by UV absorbance 
measurements using the extinction coefficients () and absorbance maxima () listed in 
Table 4.5.  A BPES buffer consisting of 6 mM Na2HPO4, 2 mM NaH2PO4, 1 mM 
Na2EDTA, and 185 mM NaCl (pH 7.0) was used for all experiments. For each 
competition dialysis assay, 200 mL of the dialysate solution containing 10 µM ligand was 
placed into a beaker. A volume of 0.2 mL (at 75 µM monomeric unit) of each of the 
DNA samples listed in Table 4.5 were pipetted into a separate 0.5 mL Pierce Slide-A-
Lyzer Mini Dialysis units (Pierce, Rockford, IL) with 3,500 MWCO membrane.  All 
dialysis units were placed in a flotation device (Pierce) and then whole unit was placed in 
the beaker containing the dialysate solution. The beaker was covered and wrapped in foil, 
and its contents were allowed to equilibrate with continuous gentle shaking for 48-72 h at 
room temperature (22-25 °C).  At the end of the equilibration period, DNA samples 
(~180 µL) were carefully removed to microfuge tubes, and were taken to a final 
concentration of 1% (w/v) sodium dodecyl sulfate (SDS) by the addition of appropriate 
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volumes of a 10% (w/v) stock solution. The total concentration of drug (Ct) within each 
dialysis unit was then determined spectrophotometrically using wavelengths and 
extinction coefficients appropriate for each ligand.  An appropriate correction for the 
slight dilution of the sample resulting from the addition of the stock SDS solution was 
made. The free ligand concentration (Cf) was determined spectrophotometrically using an 
aliquot of the dialysate solution.  The amount of bound drug (Cb) was determined by 
difference, Ct - Cf. Data were plotted as bar graphs using GraphPad Prism software. 
 
4.7.4. Critical Aggregation Concentration (CAC) Assay 
 
Compound stock solutions were prepared in DMSO at a concentration of 10 mM. 
The aggregation of styrylquinazolines and progenitor compounds was tested in 20 mM 
HEPES buffer (pH 7.0) filtered twice through 0.2 µm syringe filter.  A series of 2x 
dilutions was typically made for each compound (e.g. from 200 μM to 0.4 μM) across 
rows in 96-well plates (Corning UV plate, #3679), providing 10 data points per 
compound for the CAC analysis.  Filtered samples were prepared the same but included 
filtering 200 µM compound solutions through a 0.2 µm PVDF sterile syringe filter before 
serial dilution. All CAC measurements were performed at 25 °C (temperature is 
controlled with an absolute accuracy of 1 °C within the DynaPro instrument).  SLS 
intensities are measured at a series of different compound concentrations in aqueous 
solution (HEPES buffer) and the CAC was defined as the concentration of compound at 
which molecular aggregates first begin forming; this transition point was readily 
observed as an abrupt (nonlinear) jump in SLS intensity with increasing compound 
concentration. 
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4.7.5. Transmission Electron Microscopy (TEM) 
 
Solutions of 100 µM compounds and controls were prepared in 20 mM HEPES buffer 
(pH 7.0).  Mesh nickel grids treated with Formvar solution (0.7% Formvar powder 
dissolved in dry dichloroethane) were glow-discharged for 2 min.  At room temperature, 
15 µL of compound solution was applied to grid and allowed to sit for ~5 min.  The grids 
were then negatively stained by transferring through two droplets of 1% uranyl acetate 
and allowed to air dry.  Micrographs were recorded at 80000 magnification.   
 
 
 
Chapter 5 
Inhibitors of Streptococcus pneumoniae Surface Endonuclease EndA Discovered by 
High-Throughput Screening Using a PicoGreen Fluorescence Assay
2
 
 
5.1. Introduction 
 
Streptococcus pneumoniae (pneumococcus) is an asymptomatic colonizer of the 
human upper respiratory tract.  However, the commensal bacteria are also the causative 
agent of respiratory and life-threatening invasive diseases.  Dissemination of 
pneumococci from the nasopharynx into the lungs or bloodstream leads to otitis media, 
pneumonia, bacteremia and meningitis.
 162
 Pneumococcal diseases are traditionally 
treated with antibiotics and prevented with polysaccharide-protein conjugate vaccines.  
Unfortunately, due to the dramatic increase in antibiotic resistance and limitations of the 
currently available vaccines, the threat from pneumococcal disease remains high.  Thus, 
therapeutics directed against novel S. pneumoniae targets are needed to combat 
pneumococcal infections.  
 S. pneumoniae pathogenesis is a complex and dynamic process. The human host 
continuously deploys an array of innate and acquired immune defenses to prevent 
pneumococci from traversing epithelial barriers.
 76
 However, the pathogen expresses 
                                                 
2
 The text of this chapter is taken from a published manuscript that was coauthored with 
Professor Dmitri Kireev, Andrea Moon, Dr. Marika Midon, Professor William P. Janzen, 
Professor Alfred Pingoud, Dr. Lars Pedersen and Professor Scott F. Singleton. 
(Peterson, E. J. R.; Kireev, D.; Moon, A. F.; Midon, M.; Janzen, W. P.; Pingoud, A.; 
Pedersen, L. C.; Singleton, S. F.  Journal of Biomolecular Screening 2013, 18 (3), 247-
257) 
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numerous virulence factors, which can act alone or in concert to promote invasive 
pneumococcal disease.  The major virulence attribute of pneumococcus is the presence of 
a thick, capsular polysaccharide layer, which inhibits phagocytosis and complement 
recognition.
 163,164
 In addition to the capsule, there are many other pneumococcal 
virulence factors that are involved in the disease process.  Elucidating the roles played by 
virulence factors allows an understanding of the pathogenesis of infection and can 
provide insights into novel therapeutic options.   
 The presence of a surface nuclease involved in pneumococcal DNA transport was 
reported over 40 years ago.
 66
  S. pneumoniae is naturally transformable and the nuclease 
activity of EndA is necessary for non-transforming strand degradation and DNA uptake.
 
165
 EndA is required for efficient bacterial transformation in pneumococcus; strains with 
deactivating endA mutations exhibit an efficiency of transformation reduced more than 
100-fold compared to wild type.
 64,68,166
 Through its role in DNA uptake, EndA 
contributes to genetic plasticity, a defining characteristic of the pathogen.
 167
 This 
flexibility of pneumococcus likely facilitates responses to evolutionary pressures that 
provide a significant advantage during infection, such as evasion of host immune 
defenses or development of antibiotic resistance.
168
 
The ability of neutrophils to clear invading microorganisms by phagocytosis is 
well established.  Recently, neutrophils have been shown to produce neutrophil 
extracellular traps (NETs) that entrap and kill pathogens in the extracellular environment.
 
77
 NETs consist of neutrophil DNA as a backbone with embedded antimicrobial peptides, 
histones and proteases.  The web-like structure of NETs physically trap bacteria, but 
unlike Shigella and other pathogens,
 169
 the pneumococcus is relatively resistant to NET-
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mediated killing.
 170
 While not killed by NET constituents, pneumococcus entrapment by 
NETs impedes bacterial dissemination.  However, the surface endonuclease, EndA, 
facilitates pneumococcal escape by degrading the DNA scaffolding of the NETs.
 78
  
Mutant S. pneumoniae strains lacking EndA activity do not destroy NETs and show 
decreased virulence in mouse models of infection.
 78
  
 EndA’s importance for S. pneumoniae pathogenesis arises from its cardinal roles 
in transformation and facilitating NET escape.  Deletion of endA diminishes the 
efficiency of transformation, which could hinder the genetic variation that contributes to 
pneumococcal virulence.  Moreover, pneumococci lacking endA are not able to free 
themselves from NETs and show reduced invasive infection in mice.  Given this 
evidence, we hypothesize that small-molecule inhibition of EndA could attenuate 
pneumococcal pathogenesis and offer a novel target for the control of pneumococcal 
infection.  The discovery of potent and selective EndA inhibitors that modulate the target 
in bacteriological studies and mouse models of pneumococcal infection would be an 
important step in elucidating EndA’s role in the pathogenesis of S. pneumoniae.   
In this study, we sought to develop a simple, inexpensive, and robust high-
throughput screening (HTS) assay that directly targeted EndA and its catalytic hydrolysis 
of double-stranded DNA (dsDNA).  The use of the DNA dye ligand, PicoGreen, to 
monitor nuclease activity in real-time had been reported previously.
 171
 We adapted this 
approach for HTS with EndA.  Following optimization and validation, the PicoGreen 
nuclease assay was used to screen 4,727 compounds for EndA inhibitors.  This initial 
screen identified 32 active compounds, and subsequent assays and counter screens led to 
an EndA inhibitor with potential for further study and optimization.  This work is a 
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promising start for structure-based drug design using hits reported herein, in concert with 
additional screening efforts to discover novel EndA inhibitors. 
5.2. Assay development and validation 
 
Our main objective in developing a high-throughput screening assay for EndA 
nuclease activity was to identify selective chemical probes that would enhance our 
understanding of EndA’s role in pneumococcal virulence.  However, we were confronted 
with a challenge given the lack of HTS-compatible methods for detecting nuclease 
activity.  Traditional nuclease activity methods such as viscometry, gel electrophoresis, 
and assays using radioactive or fluorescent-labeled DNA substrates
172
 are time-
consuming, laborious and can be very expensive.  In comparison, a label-free fluorescent 
nuclease assay would be continuous, convenient, and HTS conducive.
 171,173
 Here, we 
developed and optimized an EndA nuclease assay using the fluorescent dye ligand, 
PicoGreen. We also assessed the robustness, reproducibility, and HTS compatibility of 
the PicoGreen assay to ensure its success in screening diverse drug-like small molecules 
for the inhibition of EndA. 
The use of fluorescent DNA dye provides both a precise and cost-efficient method 
of monitoring nuclease activity in vitro.  PicoGreen is a sensitive fluorescent dye widely 
used in analytical protocols in which double-stranded DNA (dsDNA) detection is needed.  
PicoGreen associates with dsDNA through intercalation, minor-groove binding, and 
electrostatic interactions,
 174
 resulting in a significant increase in fluorescence, compared 
to free dye in solution.  During reaction with EndA, the dsDNA is cleaved into small 
fragments, which have a weakened interaction with PicoGreen, resulting in lower 
fluorescence (Figure 5.1).  In contrast, reactions in the presence of EndA inhibitors 
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should retain full-length dsDNA substrate and result in strong fluorescent signal upon 
addition of PicoGreen.   
Standard fluorescence versus DNA concentration curves using several dsDNA 
substrates with 0.8 M PicoGreen were produced.  Comparing the standard curves for 
calf thymus DNA, salmon testes DNA, and lambda DNA digested with Hind III, we 
selected the latter as our substrate.  The standard curve of lambda DNA showed a linear 
signal range over three orders of magnitude and at 1.0 g/mL DNA was still in the linear 
range with sufficient fluorescence to achieve an adequate signal window (Figure 5.2A). 
The development of EndA inhibitors requires the production of active and stable 
forms of EndA for in vitro activity assays.  Unfortunately, successful over-expression 
procedures of recombinant wild-type EndA has not been reported to date, presumably 
due to uncontrolled nuclease degradation of the host DNA/RNA.  Historically, the 
enzyme has been expressed as an inactive mutant, with the catalytic active site histidine 
residue replaced with alanine (H160A).
 175,176
  Structure-based modeling suggests that the 
active site of the EndA variant can accommodate a single imidazole molecule in place of 
the missing histidine sidechain, leading to “rescue” of the nuclease activity.  Structural 
information also suggests that the C of H160A might present a steric clash with the 
imidazole, which could be relieved by a glycine substitution (H160G) at that position.  
Consistent with this theory, the EndA(H160G) mutant is considerably more active than 
EndA(H160A).
 175
  We therefore elected to use EndA(H160G) for assay development, 
and imidazole can be considered a cofactor in assays measuring the imidazole-dependent 
nuclease activity of EndA(H160G).
 177
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To determine the optimum concentration of imidazole, the kinetics of 10 mM 
EndA(H160G) catalyzed DNA hydrolysis were measured using the PicoGreen assay at 
imidazole concentrations ranging from 0 to 200 mM (Figure 5.2B).  The observed 
enzyme velocity reached a maximum at 50 mM imidazole, then decreased at higher 
concentrations.  This inverse effect was reported previously with EndA(H160G) and is 
likely explained by the elevated ionic strength of the buffer at high imidazole 
concentrations.
 175
  An imidazole concentration of 25 mM was chosen as the optimal 
concentration for the PicoGreen assay. 
In the presence of 25 mM imidazole and a saturating concentration of Hind III 
digested lambda DNA (1 g/mL), EndA’s nuclease activity increased monotonically with 
initial EndA concentration (Figure 5.4).  An EndA concentration of 15 nM was selected 
for further experiments because this was the lowest EndA concentration to produce 
approximately linear enzyme activity over a reasonable time range and sufficient dsDNA 
digestion to achieve an adequate signal window.  Optimized conditions included 15 nM 
EndA, 1 g/mL DNA, and 25 mM imidazole.  Since EndA has been shown to be a 
divalent metal ion dependent nuclease,
 176
 MgCl2 was
 
added to the reaction at 5 mM.  
Under these conditions at room temperature, the PicoGreen assay demonstrated linear 
nuclease kinetics to 40 min (Figure 5.4).  We elected to use 30 min as the reaction time 
to remain comfortably within the assay’s linear dynamic range.  
 Another advantage of the PicoGreen assay is its adaptation for real-time 
monitoring of PicoGreen fluorescence changes, as EndA nuclease activity is unaffected 
by the presence of PicoGreen dye (data not shown).  This allows kinetic and mechanistic 
parameters of putative inhibitors to be explored using the same assay method. 
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Given that small-molecule library samples are dissolved in DMSO in preparation 
for screening, the effect of DMSO on EndA activity was investigated at several different 
DMSO concentrations, up to 10% (vol/vol) (Figure 5.5).  There was no significant 
impact on EndA’s observed initial velocity by DMSO up to 1% (vol/vol).  At 5% and 
10% DMSO, there was an apparent increase in EndA activity.  This increased activity has 
been observed with other DNA processing enzymes and one likely explanation is that 
DMSO molecules replace water molecules around the DNA, thus increasing the affinity 
of the enzyme for DNA.
 178
 The final DMSO concentration used for screening was 1% 
(vol/vol). 
 In other studies, we examined the effect of bovine serum albumin (BSA) and 
detergent on the signal-to-background window of the PicoGreen assay.  In screening 
assays, BSA provides an alternative interaction surface for promiscuous small-molecule 
aggregates and detergent disrupts the formation of colloidal aggregates that can 
nonspecifically inhibit enzyme activity.
 179
  The influence of BSA and TritonX-100 were 
each evaluated over three concentration points and no substantial effects were observed 
on the signal-to-background window (Figure 5.6).  To efficiently reduce nonspecific 
aggregation-based inhibition by promiscuous inhibitors, 0.01% TritonX-100 and 1.5 M 
BSA were selected as final concentrations.  
To assess the reproducibility of the PicoGreen assay, a number of test 384-well 
plates were evaluated for interplate and interday variability.  Over a span of 3 days, 9 
replicate assay plates were run under the optimized conditions described above and used 
to compile the mean control signals (Figure 5.7) for Z factor calculation. 98  The 
maximum signal or inhibited controls (32 per plate, two columns of a 384-well plate) 
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consisted of wells containing EndA, DNA, imidazole and 50 mM EDTA in buffer.  The 
minimum signal controls (32 per plate, 2 columns of a 384-well plate) consisted of wells 
containing EndA, DNA, imidazole and 1% DMSO in buffer.   The PicoGreen reagent 
was added after 30 min, followed by measurement of fluorescent intensity signal using an 
EnVision plate reader.  The average control signals for interplate assays performed on the 
same day were analyzed and used to calculate the Z' values of 0.61, 0.63 and 0.64 for 
each day.  Additionally, the interday variability in the maximum signal control was less 
than 10%.  Overall, these results are characteristic of a high-quality assay suitable for 
HTS, and Z' values were found to improve with use of liquid handling equipment. 
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Figure 5.1. Cartoon of PicoGreen screening assay for discovery of EndA inhibitors. 
Inhibitors of EndA prevent the EndA-mediated degradation of dsDNA. Interaction of PicoGreen 
with dsDNA results in an increased fluorescence over free PicoGreen and PicoGreen interaction 
with ssDNA and short dsDNA fragments. 
 
 
 
 
Figure 5.2. Assay optimization with respect to (A) DNA substrate in the presence of 
PicoGreen and (B) imidazole.  (A) Hind III digested lambda DNA in the presence of 0.8 M 
PicoGreen.  (B) Scatter plot of EndA reaction initial velocity in the presence of various amounts 
of imidazole. The data presented are mean  SD of triplicate wells (n = 3). 
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Figure 5.3. Titration of EndA(H160G) in optimized assay buffer.  Timecourse 
experiments using PicoGreen nuclease assay were performed at different EndA(H160G) 
concentrations.  The data presented are mean  SD of triplicate wells (n = 3). 
 
 
 
 
 
 
Figure 5.4. Assay optimization with respect to time and enzyme dependence. 
Reaction timecourse in the () presence or () absence of 15 nM EndA(H160G). Each 
data point represents the mean  SD of triplicate wells (n = 3). 
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Figure 5.5. Bar graph depicting initial velocities of EndA reaction in the presence of 
various amounts of DMSO.  The data presented are mean  SD of triplicate wells (n = 3). 
 
 
 
 
 
 
Figure 5.6. Optimization of TritonX-100 and BSA in the PicoGreen nuclease assay.  
Each replicate (n = 16) was plotted for maximum and minimum signal controls while TritonX-
100 and BSA were each titrated over three concentration points.  We saw little effect on the 
control signals and determined that 0.01% TritonX-100 and 1.5 M BSA would be appropriate in 
the assay to decrease nonspecific binding and minimize the effect of aggregate-based inhibition.  
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Figure 5.7. EndA PicoGreen assay validation over multiple plates and multiple days.  
The 384-well plates were divided into 32 wells of minimum signal (gray circles) and 32 wells of 
maximum signal (black signal) control reactions.  The variation was measured between three 
individual runs on the same day and the variation between runs on three separate days.  Without 
using liquid handling system, the overall Z' for 96 wells on days 1, 2, and 3 were 0.61, 0.63, and 
0.64, respectively.  
5.3. Pilot screen of LOPAC library 
 
Using the optimized and validated PicoGreen assay, we screened the Library of 
Pharmacologically Active Compounds (LOPAC) against EndA(H160G) as a pilot screen 
study.  The LOPAC contains 1,280 biologically active compounds that were compressed 
into four 384-well plates.  The LOPAC was assessed in duplicate for EndA inhibition at a 
final compound concentration of 10 M.  The LOPAC pilot screening results 
demonstrated a normal distribution centered on a mean of 6% inhibition with a standard 
deviation (SD) of 8% (Figure 5.8A).  Moreover, the LOPAC pilot screen was 
characterized by an average Z factor of 0.87 (Figure 5.8B), and demonstrated strong 
correlation between replicates (Figure 5.8C).  To ensure that we would only identify 
high-quality hits, we used a selection criterion of > 40% inhibition, which represented 
more than 4 standard deviations away from the minimum signal control.  As summarized 
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in Figure 5.9, we identified 16 active compounds from the primary LOPAC screen and 
14 of these compounds were obtained as DMSO stocks for IC50 analysis.  In total, 9 of 14 
compounds were confirmed as true actives, and 3 compounds, MK-886 (PubChem CID: 
4519262), 6-hydroxy-DL-DOPA (PubChem CID: 107794), and myricetin (PubChem 
CID: 5281672), had IC50 values in the nanomolar range.  Despite their potency against 
EndA, we found these screening hits also inhibited many other non-related enzymes,
 158
 
and studies suggest they may be aggregate-forming inhibitors.
 154
  While the LOPAC 
pilot screen provided a number of novel biochemical inhibitors of EndA(H160G), the 
compounds were of the promiscuous type and emphasized the need for additional 
screening.  Importantly, however, the LOPAC pilot screen validated the PicoGreen assay 
as a robust and reproducible method for high-throughput screening of compound 
libraries. 
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Figure 5.8. Results from the EndA pilot screen of LOPAC.  (A) Frequency distribution 
of the LOPAC pilot screen relative inhibition results depicted as a histogram, where the number 
of compounds in each bin (1% width) is plotted on a log scale.  (B) Z' factor analysis of the 8 
plates assayed during LOPAC pilot screen in duplicate.  32 wells of minimum controls (0.1% 
DMSO final) and 32 wells of maximum activity controls (50 mM EDTA final) were used to 
calculate the Z' factor.  Dashed line indicates the average Z' = 0.87.  (C) Correlation plot of the 
relative inhibition from duplicate runs of EndA LOPAC screen with solid line indicating perfect 
1:1 correlation.  
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Figure 5.9. Critical Path for EndA Inhibitor Discovery. In the primary screens, 1,280 and 
4,727 compounds were assessed from the LOPAC and UNC Kinase Focus Set, respectively. In 
the LOPAC screen, 16 actives were identified (1.6% hit rate) of which 14 were selected to re-test 
in dose-response format. Of these, 9 compounds were confirmed as inhibitors (64% confirmation 
rate). In the Kinase Focus Set screen, 79 actives were identified (1.7% hit rate), of which 77 were 
selected to re-test in dose-response format, and 32 compounds were confirmed as inhibitors (42% 
confirmation rate). Of these, seven were available as dry powder compounds, all seven of which 
replicated dose-response behavior. Six of the seven compounds passed the counter-screens for 
interfering compounds and imidazole-competitive compounds. Based on its potent IC50 and other 
acceptable characteristics, UNC10103486 was prioritized for evaluaiton in the orthogonal assay 
for plasmid conversion. 
 
5.4. Kinase focus set screening 
 
The Kinase Focus Set was selected as the compound collection for our continuing 
screening efforts to identify inhibitors of EndA nuclease activity.  The Kinase Focus Set 
was designed at the University of North Carolina at Chapel Hill using a combination of 
kinase pharmacophore-based searching and selection from vendor kinase directed sets.  
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Although EndA is not a kinase, the small-molecules of the Kinase Focus Set were of a 
manageable number, represented a diversity of scaffolds, and all were “rule of five” 
compliant.
 111
 The Kinase Focus Set has been routinely screened at UNC using non-
kinase targets.  Moreover, the Kinase Focus Set has yielded selective and potent 
inhibitors against another nucleic acid-processing enzyme.
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Compounds from the Kinase Focus Set were screened against EndA in singleton 
at 10 M from 1 mM DMSO stocks using the PicoGreen assay.  The screening results 
gave a normal distribution with a mean of 5% inhibition and a SD of 11% (Figure 
5.10A).  Overall, the average Z = 0.87 for the 16 analyzed plates (Figure 5.10B).  The 
screen yielded 79 compounds with  40% inhibition (3 above the mean) and a 1.7% 
primary screen hit rate (Figure 5.9).  We eliminated 2 compounds with unfavorable 
physiochemical properties and performed dose-response analysis of 77 compounds from 
their 10 mM DMSO stocks from the CICBDD.  Concentration-response evaluations were 
carried out in duplicate for the 77 initial actives the results confirmed 32 out of the 77 
compounds as true actives with IC50 ≤ 30 M (i.e., 42% confirmation rate). Raw data for 
duplicate runs of a validated hit compound demonstrated reproducible dose-dependent 
inhibition of enzyme activity over the concentrations tested and a mean IC50 = 9  1 M 
(Figure 5.11). 
The primary screen of the Kinase Focus Set using the EndA assay showed a 
remarkably high overall confirmed hit rate (0.68%), calculated as the percentage of 
confirmed hits (IC50 ≤ 30 M) from the entire Kinase Focus Set library (Figure 5.9).  
With respect to overall confirmed hit rate, the EndA screen was ranked fourth among 12 
screening campaigns against the Kinase Focus Set at UNC. The 3 screens that showed 
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higher hit rates (between 0.85% and 1.18%) all targeted protein kinases; the 8 other 
screens with lower hit rates were not against kinases.  It is unclear why compounds 
featuring “kinase-like” chemical motifs (mainly by mimicking the adenosine moiety of 
ATP) were so efficient on a target lacking a well-defined ligand/co-factor pocket.
 175
 A 
plausible hypothesis is that prospective kinase inhibitors may fortuitously possess a 
chemical feature that also makes them also potent against endonucleases.  For instance, 
most known kinase inhibitors are designed to have a common structural fragment called 
the hinge-binding motif.  The hinge-binding motif is a packed set of hydrogen-bond 
donors and acceptors that bind to a portion of the protein backbone connecting the large 
and small lobes of the kinase domain.
 180
 However, it is common for such a motif to also 
have chelating properties and, hence, may also bind the Mg
2+
 ion present in the EndA 
catalytic site.  Regardless, the overall screening statistics indicate a high-quality assay 
and confirm the utility of the PicoGreen assay to discover novel inhibitors of 
EndA(H160G) by HTS. 
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Figure 5.10. Kinase Focus Set HTS results.  (A) Frequency distribution of Kinase Focus 
Set relative inhibition results depicted as a histogram, where the number of compounds in each 
bin (1% width) is plotted on a linear scale.  (B) Plot of the Z' factors from the 16 plates assayed 
during Kinase Focus Set HTS.  The average Z' = 0.87 and is represented by the dashed line. 
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Figure 5.11. Reproducible concentration-response measurements of a validated 
compound from the Kinase Focus Set screen.  The calculated IC50 = 9  1 M was 
reproducible for duplicate runs: n = 1 () and n = 2 (). 
 
5.5. Biochemical characterization of confirmed actives 
 
Of the 32 compounds identified and confirmed as inhibitors, 7 were available 
from commercial sources.  We obtained the 7 compounds, freshly prepared stocks at 10 
mM in 100% DMSO, and retested the 7 compounds in dose-response and performed 
further assays to better characterize their biochemical activity and prioritize them for 
follow-up microbiological experiments.  To counter-screen against possible off-target 
effects, we employed two assays that enabled us to identify false-positives that were 
identified due to DNA-binding by the test compounds or assay interference.  We also 
tested inhibitors to determine whether binding was reversible.  Finally, we employed a 
plasmid conversion nuclease assay
175,176
 to confirm inhibition of EndA by an orthogonal 
method.  
 A compound that binds DNA could produce a false-positive in the PicoGreen 
assay by sequestering the DNA, thereby preventing EndA nuclease activity.  To test for 
DNA binding, we employed the real-time PicoGreen nuclease assay in the absence of 
EndA(H160G) at three concentrations (1, 30, 100 M final) of test compound.  True 
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inhibitors of EndA had no effect on fluorescence, while compounds that bind DNA or 
interfere with the DNA-PicoGreen interaction decreased the fluorescence signal.  Only 1 
of the 7 compounds showed a significant effect in the counter-screen (Figure 5.12), 
suggesting that this compound may interact with dsDNA.  Interestingly, this compound’s 
structure contains a 2-hydroxyphenyl hydrazide moiety, which has previously been 
identified as problematic in two studies.
 116,181
 Indeed, the compound was annotated as 
“active” in 7 out 17 assays in the UNC database, 31 out of 65 assays in the ChemBL 
(ChemBL CID CHEMBL1981200), and 59 out of 545 assays in the PubChem database 
(PubChem CID 5811720).  Of the 6 remaining reordered compounds, UNC10103486 
showed reproducible dose-dependent activity with the most potent IC50, no effect in the 
counter-screen, and also no activity in other assays recorded in the UNC database.  
Therefore, we focused our attention on the biochemical characterization of compound 
UNC10103486 (Figure 5.13A). 
The PicoGreen nuclease assay measured the imidazole-dependent nuclease 
activity of EndA(H160G).  Therefore, it was possible that some of the identified 
compounds inhibited the rescued EndA variant by interfering with imidazole binding to 
the active site.  To test compound UNC10103486 for an imidazole-dependent mechanism 
of action, EndA(H160G) activity was measured by the real-time PicoGreen nuclease 
assay as a function of imidazole concentration at different inhibitor concentrations.  
Analysis of the resulting velocity-imidazole concentration curves revealed that 
UNC10103486 inhibition was not competitive with imidazole (Figure 5.13B).  
Moreover, calculation of IC50 from the velocity-imidazole concentration curves 
determined a constant IC50 = 16  1 M over increasing imidazole concentrations 
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(Figure. 5.13C) and confirmed UNC1013486 was not competitive with imidazole. 
  To determine whether UNC10103486 binding was reversible, we adapted the 
real-time PicoGreen nuclease assay with a rapid dilution assay. Briefly, inhibitor was 
allowed to bind EndA at a concentration expected to inhibit roughly 95% of EndA 
activity, then diluted to a concentration expected to inhibit only 5% of EndA activity. A 
reversible inhibitor would dissociate quickly, allowing immediate recovery of enzyme 
activity; a slowly reversible inhibitor would allow a gradual increase in activity; and an 
irreversible inhibitor would completely prevent the recovery of enzyme activity.  Dilution 
of EndA inhibited by UNC10103486 did allow a gradual recovery of EndA, with an 
initial velocity of 62  22 countsmin-1, compared to 128  6 countsmin-1 with DMSO 
alone (Figure 5.13D).  This confirmed a reversible binding mechanism for 
UNC10103486. 
We confirmed the inhibition of EndA by UNC10103486 by an alternative 
nuclease assay for plasmid DNA conversion.  In this simple assay, supercoiled plasmid 
DNA is nicked by EndA and transformed into an open circular structure that migrates 
significantly more slowly during electrophoresis on an agarose gel.  Further plasmid 
cleavage leads to a linear DNA form that migrates as a band between the supercoiled and 
open circular forms.  Progressively, more cleavage produces oligonucleotides of various 
sizes, which appear as a “smear” of faster-migrating products on the agarose gel.  We 
monitored the DNA products in the presence of UNC10103486 and found a dose-
dependent inhibition of plasmid DNA cleavage (Figure 5.13E).  EndA inhibition in the 
plasmid DNA cleavage assay confirmed the activity of UNC10103486 and also that its 
mechanism was independent of the PicoGreen assay detection method. 
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Figure 5.12. Evaluation of reordered Kinase Focus Set hits by DNA binding 
counter-screen assay.  Each inhibitor was evaluated in triplicate (n = 3) at three different 
concentrations and their fluorescence intensity count was averaged over 20 min.  Each bar 
represents the average of three runs + SD.  Only compound UNC10104326 decreased the 
fluorescence signal and likely interacts with dsDNA. 
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Figure 5.13. Biochemical characterization of a promising EndA inhibitor. (A) 
Structure of compound UNC10103486. (B) Compound UNC10103486 is non-competitive with 
respect to imidazole. (C) IC50 analysis of the velocity-imidazole concentration curves determines 
an averaged IC50 = 16  1 M in the presence of increasing imidazole. (D) Initial velocities from 
rapid dilution reversibility test suggest compound UNC10103486 is a reversible inhibitor of 
EndA. (E) Plasmid DNA conversion EndA(160G) assay timecourse in the absence or presence of 
30 M UNC10103486.  EndA-mediated plasmid conversion is significantly inhibited in the 
presence of UNC10103486.  Timepoints were taken at 10 sec, 30 sec, 1 min, 2 min, 5 min, 10 
min, 15 min and 20 min.  Lane M is 1 kb DNA marker and lane P is pBluescript II SK(+) plasmid 
only. 
 
5.6. Conclusions 
 
To the best of our knowledge, we have established the first reported HTS assay to 
identify compounds that inhibit nuclease activity.  Using a nuclease assay based on the 
differential fluorescence output of PicoGreen, we optimized the assay for HTS against an 
imidazole-rescued variant EndA(H160G).  Following stringent assay validation, 
including a pilot screen of LOPAC, the assay was used to screen 4,727 compounds from 
the Kinase Focus Set.  The screen had an average Z' = 0.87 and resulted in the 
identification of 32 confirmed actives.  From these hits, the compound UNC10103486 
was further validated as an inhibitor in an orthogonal EndA nuclease assay and acts via a 
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mechanism independent of PicoGreen and imidazole.  
The validation of the PicoGreen nuclease assay and its use in HTS is fundamental 
to the search for nuclease inhibitors.  Specifically, drugs that inhibit nuclease activity 
may help to improve the outcome of bacterial infection with Streptococcus pyogenes and 
Staphylococcus aureus, which also express nucleases that facilitate NET evasion.
 182,183 
Additionally, a major advantage of the PicoGreen nuclease assay is its versatility as both 
a screening assay and for monitoring nuclease activity in real-time.  Such broad 
application of this technology allows for a consistent transition from primary screening to 
more in-depth studies of binding properties and mechanism of inhibition.  
The S. pneumoniae surface endonuclease EndA has at least two functions that are 
important in pneumococcal disease.  EndA is responsible for DNA degradation and 
transport during transformation, which contributes to pneumococcal genome variation.  
Genetic variation, including both de novo adaptation and acquisition of genes conferring 
antibiotic resistance or virulence factors, is important for the persistence of the pathogen 
and progression of disease.  In addition, the superficial location of EndA permits 
extracellular degradation of the DNA component of NETs, thereby facilitating 
pneumococcal dissemination and increasing the risk of invasive infection.  These 
activities of EndA contribute to pathogenesis, making the pneumococcal nuclease an 
attractive target for controlling S. pneumoniae diseases. Currently, experiments are 
underway to evaluate UNC10103486 and other promising in vitro inhibitors of EndA 
using live bacteria assays for transformation and NET degradation.  The facile 
identification of small-molecule inhibitors is an important first step for developing 
 110 
pharmacologic probes of EndA to address its roles in pneumococcal virulence and to 
establish it as a druggable target for combating pneumococcal infection. 
5.7. Materials and methods 
 
 
5.7.1. Materials and equipment 
 
The Quant-it PicoGreen dsDNA Reagent (Cat. No. P7581) was purchased from 
Molecular Probes by Life Technologies (Grand Island, NY).  Lambda DNA-Hind III 
digest (Cat. No. N3012L) was purchased from New England Biolabs (Ipswich, MA). The 
cloning, production, and purification of EndA(H160G) were reported previously.
17
  
Unless otherwise stated, all other reagents used for buffers and assays were purchased 
from Thermo Fisher Scientific (Waltham, MA).  
 
5.7.2. LOPAC compound collection 
 The Library of Pharmacologically Active Compounds (LOPAC) was purchased 
from Sigma-Aldrich as 10 mM stocks in DMSO.  The library was previously prepared as 
1 L samples in 384-well V-bottom polypropylene microplates (Greiner, Monroe, NC), 
sealed by a ALPS 3000 microplate heat sealer (Thermo Fisher Scientific) and stored at -
20 C.  On the day of use, the compounds were thawed and diluted to 100 M (10x final 
concentration) in R Buffer (Reaction Buffer: 25 mM imidazole, 20 mM Tris-HCl pH 8.0, 
10 mM sodium acetate, 10 mM MES, 25 mM NaCl, 5 mM MgCl2 , 1.5 M BSA, and 
0.01% v/v Triton X-100) over 2 steps using a Thermo Fisher Scientific Multidrop Combi 
Reagent Dispenser and Multimek NSX-1536 assay workstation system fitted with a 384-
well head (Nanoscreen, Charleston, SC).  Finally, 1 L of this stock was spotted into the 
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wells of a 384-well black PerkinElmer Proxiplate (Waltham, MA) for assay use, as 
described below. 
 
5.7.3. Kinase Focus Set 
 The Kinase Focus Set was designed and purchased by the Center for Integrative 
Chemical Biology and Drug Discovery (CICBDD).  Design of this library was based on 
selection from vendor kinase-directed sets.  Initially, more than 100K compounds were 
received from various vendors, in the form of SD files.   The vendors had originally 
designed these kinase-focused libraries using one or more of the following approaches: 
(1) searching virtual and physical general purpose libraries for compounds similar to 
known kinase inhibitors; (2) selecting or synthesizing compounds having a hinge-binding 
motif; i.e., adenosine bioisosters with a high likelihood to bind the backbone in the kinase 
hinge-binding motif conserved in every kinase structure; and (3) structure- or ligand-
based virtual screening on representative kinase structures.  In order to reduce the size of 
the library, while preserving its efficiency in screening, we removed structural duplicates, 
filtered out compounds that did not satisfy the “rule-of-five”18 and, finally, performed a 
cluster-based selection.  Clustering was performed by means of the Pipeline Pilot 
software (Pipeline Pilot, v. 8.5, Accelrys Software Inc., 2011) in such a way that 
compounds belonging to the same cluster had pairwise similarity of 50% or more 
(according to Tanimoto metrics with ECFP4 descriptors).  Once clustered, we selected 3 
to 10 representative compounds, depending on the cluster size.  In the end, the CICBDD 
acquired 4,727 representative compounds that constitute the Kinase Focus Set. 
The compound plates of the Kinase Focus Set were prepared by resuspending the 
powder stock to 1 mM in 100% DMSO in barcoded glass vials with sonication using a 
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Covaris S2 sonicator (Covaris, Woburn, MA).  Compounds were plated at 1 mM in 100% 
DMSO in 384-well V-bottom polypropylene microplates using a Tecan Genesis 200 
(Münnedorf, Switzerland).  A Multimek spotted 1 L of the 1 mM compounds into 384-
well V-bottom polypropylene microplates and plates were heat sealed and stored at -20 
ºC.  During screening, these previously prepared plates were thawed and diluted to 100 
M by a single addition of R Buffer, and 1 L of this stock was spotted into the wells of 
a 384-well Proxiplate.  
 
5.7.4. PicoGreen Nuclease Assay 
 The assay was performed by using a Multidrop dispenser to add 1 L of 10% 
(v/v) DMSO in the left two columns (columns 1, 2) for the positive control reactions.  In 
the right two columns (columns 23, 24), 1 L of 500 mM EDTA was spotted for the 
negative control reactions. Assay reactions were carried out directly in the Proxiplate 
wells containing 1 L compounds or controls.  The reaction volume in each well was 10 
L, and final concentrations of compound and DMSO were 10 M and 1% (v/v), 
respectively.  A 2x solution of EndA(H160G), containing 30 nM EndA, was prepared in 
R Buffer.  To all wells of the assay plates, 4.5 L of the 2x EndA(H160G) in R Buffer 
was added using a Multidrop dispenser.  EndA was allowed to pre-incubate with 
compounds and controls for 20 min in a 37 C air incubator.  Following pre-incubation, a 
2x solution of lambda DNA-Hind III digest (2 g/mL) in R Buffer was added at a volume 
of 4.5 L to each well.  Reaction time began immediately upon addition of the dsDNA 
substrate and was allowed to proceed for 30 min at room temperature.  The plates were 
quenched by adding 10 L of 2x PicoGreen Reagent (1.6 M or 1/200 dilution) in Q 
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Buffer (Quench Buffer: 10 mM Tris-HCl pH 8.0, 20 mM EDTA) to each well.  Plates 
were incubated at ambient temperature in the dark for 5 min prior to reading on an 
EnVision Multilabel Reader (PerkinElmer) using excitation wavelength of 480 nm and 
emission wavelength of 520 nm.  
 Compounds being evaluated for dose-response runs were attained from frozen 10 
mM stocks in 100% DMSO. The Kinase Focus Set hits were plated as 3-fold dilutions 
over 10 points using the Tecan in 384-well V-bottom polypropylene microplates.  The 
dose-response curves for LOPAC hits were prepared as 3-fold dilutions over 10 points 
using a multi-channel pipette.  Compound titration series of all hits for IC50 evaluation 
were spotted at 1 L by a Multimek instrument into 384-well V-bottom microplates and 
diluted 10-fold in R Buffer using a Multidrop dispenser.  The diluted titrations were then 
spotted at 1 L into 384-well black Proxiplates (Perkin Elmer) in duplicate, and reagents 
were added to initiate the assay as described above.  The final top concentration of dose-
response curves was 30 M compound (1% v/v DMSO).  
 
5.7.5. Data anlysis 
 The fluorescence count of each well was measured using excitation wavelength of 
480 nm and emission wavelength of 520 nm on the EnVision plate reader.  Screening 
data was processed using ScreenAble software (Screenable Solutions).  The relative 
inhibition, expressed as a percentage of the inhibition of assay signal change elicited by 
50 mM EDTA, was determined on a plate-to-plate basis by comparing the fluorescence 
count per compound well (F) with the plate-averaged control wells (n = 32 for each 
control), using the following relationship: 
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                                                          (1) 
 
where min and max are the plate-averages of the minimum signal (maximum EndA 
activity, 1% v/v DMSO added) and maximum signal (fully inhibited EndA, 50 mM 
EDTA added) controls, respectively.  
  Compound IC50 values were calculated by first converting the F count to percent 
inhibition with respect to on-plate controls and then fitting the percent inhibition values 
to curve equations using ScreenAble or Prism (GraphPad Software, San Diego, CA).  The 
IC50 values of the Kinase Focus Set hits were calculated using ScreenAble with a 3- or 4-
parameter curve fit.  The LOPAC hits were analyzed in Prism using a one-site specific 
binding with adjustable Hill slope and Bmin parameters. 
 
5.7.6. Plasmid DNA conversion assay 
 
EndA was diluted stepwise to 100 pM in activity buffer (20 mM Tris-HCl pH 8.0, 
5 mM MgCl2, 50 mM imidazole) and incubated with 15 ng/ml of supercoiled pBluescript 
II SK(+) plasmid (Stratagene), in the presence of DMSO or inhibitor.  At scheduled 
timepoints, the reactions were quenched by addition of loading dye containing EDTA 
(250 mM).  Reaction products were separated by electrophoresis on an agarose-TBE gel 
(0.8 % w/v).  DNA species in the gel were visualized by ethidum bromide staining and 
scanned with the Gene Genius Bio imaging system (Syngene). 
 
5.7.7. Real-time PicoGreen nuclease assay  
 
All reactions were carried out in 96-well plates (Corning 3991 black flat-bottom) 
at 25°C inside the POLARstar Ultima plate reader (BMG labtech).  Fluorescent intensity 
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counts were recorded at excitation wavelenth, 480 nm, and emission wavelength, 520 nm.  
Reaction mixtures (100 l) consisted of 5 L of 100% DMSO or 20x inhibitor in 100% 
DMSO and 90 l of 16.6 nM EndA(H160G) in RT buffer (Real-time buffer: 25 mM 
imidazole, 20 mM Tris-HCl pH 8.0, 10 mM sodium acetate, 10 mM MES, 25 mM NaCl, 
5 mM MgCl).  Reaction was initialized by addition of 5 l of 20x lambda DNA-Hind III 
digest (1 g/mL final) and 20x PicoGreen (0.3 M final) in RT buffer.  After 
initialization, shaking for 30 seconds mixed the plate and plate data recorded every 1 min 
for 70 min.  Initial velocities were calculated and used in further analysis.  The counter-
screen assay was conducted following the same protocol used in the Real-time PicoGreen 
nuclease assay excluding EndA(H160G).  In detail, inhibitors were diluted to 20x 
concentrations (1, 30, 100 M final) in 100% DMSO and 5 L was added to each well 
followed by 95 L of lambda DNA-Hind III digest (1.5 M final) and PicoGreen (0.3 
M final).  The fluorescent intensity counts were recorded and averaged over 10-15 min 
for use in further analysis.  The rapid-dilution assay was also performed using the Real-
time PicoGreen nuclease assay with EndA(H160G) pre-incubated with a high 
concentration of inhibitor.  Specifically, 2 L of a solution of 1 M EndA mixed with 90 
M inhibitor for 20 min at room temperature was diluted into 95 l of RT buffer.  
Reaction was started with 5 L addition of 20x lambda DNA-Hind III digest (1 g/mL 
final) and 20x PicoGreen (0.3 M final) in RT buffer and proceeded as described above 
for the Real-time PicoGreen nuclease assay. 
 
Chapter 6 
Conclusions 
 
The introduction and widespread use of antibiotics beginning in the 1930’s was 
believed to be the solution to one of humanity’s greatest threats, disease-causing bacteria.  
However, decades later, we realize the struggle is far from over as bacterial populations 
are gravely resistant to antibiotics.  While the incidence of resistant bacterial strains is 
increasing at an alarming rate, there is a shortage of novel drugs to treat bacterial 
infections.  Our most often prescribed antibacterial drugs are being used and misused to 
the point where resistance has eroded their utility.  Additionally, there is little enthusiasm 
in the pharmaceutical sector to invest in antibacterial research and development.  In this 
regard, incentive policies are needed to encourage the development of new antibiotics, 
but also those that bear in mind drug resistance when pharmaceutical companies are 
marketing and selling their product.  Such incentives should also put a greater emphasis 
on creative, new strategies to address the antibiotic pipeline problem, instead of 
chemicals that belong to existing drug classes and are likely to be rendered obsolete by 
resistance.  Towards this end, we have proposed inhibiting recombination enzymes to 
ultimately target the underlying mechanisms involved in accelerated bacterial evolution 
and the development of antibiotic resistance.  
The key recombination enzymes, RecA and EndA, are involved in bacterial stress 
response pathways (i.e., SOS and competence for transformation) that are responsible for 
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accelerated genetic changes induced by antibiotic exposure.  In the absence of any known 
inhibitors, we sought to develop small molecule inhibitors of RecA and EndA to dissect 
and further understand their role in accelerated bacterial evolution.  This dissertation has 
examined high-throughput screening (HTS) programs towards the discovery of such 
molecules.  We screened large compound libraries to identify and evaluate lead series 
that selectively inhibit RecA or EndA.  
The search for an inhibitor of any protein begins with an assay capable of 
detecting the influence that a small molecule has on the activity of the protein.  Over the 
course of this dissertation, we have detailed the development of novel assays that were 
employed to identify RecA and EndA inhibitors.  As RecA is a DNA-dependent ATPase, 
we developed the RecA Transcreener assay to identify compounds that prevented the 
RecA-dependent generation of ADP from ATP.  The RecA Transcreener assay was 
optimized for HTS compatibility and was successfully used to screen 113,447 
compounds.  The detailed results from this screening campaign are presented in this 
dissertation along with a broad analysis of follow-up tests for bacteriological activity.  
While there were 8 tractable hit series identified from the RecA screen, most of this data 
is of commercial interest and not discussed here.  However, one group of small molecules, 
the styrylquinazolines, had potent in vitro activity against RecA and is extensively 
examined.  The convincing biochemical RecA inhibition of the styrylquinazolines carried 
over to bacteriological studies and stimulated mechanistic studies of these compounds.  
Styrylquinazoline analogs were found to have little interaction with double-stranded 
DNA (dsDNA) by thermal denaturation and competition dialysis studies.  Experiments 
monitoring aggregation suggest styrylquinazolines form colloidal aggregates that could 
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nonspecifically inhibit RecA and may account for their observed activity.  Despite this, 
styrylquinazolines have activity consistent with RecA inhibitors acting on target and are 
being studied further for their utility as chemical adjuvants to intervene in the 
development of antibiotic resistance.  Other future studies in the RecA inhibitor 
discovery program include considering the weak correlation between in vitro enzyme 
inhibition and activity in bacteria as discussed in Chapter 3.  This lack of relationship 
may be attributed to the poor physiochemical properties of the compounds that were 
discovered from screening the CICBDD’s “diversity” library and may encourage further 
screening of more select libraries and particularly those with molecules designed to enter 
and stay active in bacteria.   
The discovery of EndA inhibitors utilized an assay that assessed EndA-mediated 
digestion of double stranded DNA by fluorescence changes in the DNA dye ligand, 
PicoGreen.  After development and optimization for HTS, the EndA PicoGreen assay 
was used to screen 4,727 small molecules.  We discovered ten confirmed active 
compounds with strong potency for EndA, three of which have promising mechanisms of 
inhibition.  The future of the EndA inhibitor discovery program will consist of 
developing bacteriological activity assays for routine testing as well as additional 
screening efforts to identify other lead scaffolds.  The libraries for this additional 
screening should contain diverse compounds with favorable physiochemical properties, 
but the need for compounds with that allow entry into and prevention of efflux from 
bacteria may not be required because EndA is surface localized.  This characteristic of 
EndA may allow many structural classes to be explored as inhibitors and may ease the 
identification of inhibitors with bacteriological and in vivo activity.   
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Taken together, the work presented in this dissertation provides a foundation for 
the discovery of novel inhibitors of RecA and EndA.  We provide evidence that RecA 
and EndA are potentially exciting new targets in the intervention of bacterial stress 
response pathways that lead to antibiotic resistance. This work may also guide future 
programs focused on inhibiting other DNA-processing enzymes that facilitate accelerated 
bacterial evolution (i.e. RecBCD).  We hope that this work will progress and one day 
there will be drugs available that prevent the development of antibiotic resistance and 
support the fight against bacterial infectious disease.  Even then, the existence of 
pathogenic bacteria means humans and microbes are locked in a contest between “our 
wits and their genes.” 184 This quote from Nobel laureate Dr. Joshua Lederberg illustrates 
the need for research programs that recognize and respond to ongoing changes in 
antibiotic resistance and facilitate antibiotic discovery in perpetuity.
Appendix A 
Inhibitors of Streptococcus pneumoniae Surface Endonuclease EndA Identified by 
Virtual Screening 
A.1. Introduction 
Streptococcus pneumoniae (pneumococcus) commonly colonizes the upper 
respiratory tract of healthy humans. However, dissemination of the bacteria from the 
nasopharynx can result in serious invasive pneumococcal disease, bacteremia, meningitis 
and often death.
 162
  To prevent pneumococci from traversing epithelial barriers, the 
human host continuously deploys an array of innate and acquired immune defenses.
 76
 
However, the pathogen expresses numerous virulence factors, which act alone or in 
concert to promote invasive pneumococcal infection.  Elucidating the roles played by 
virulence factors allows an understanding of the pathogenesis of infection and can 
provide insights into novel therapeutic options. 
Among its virulence factors, S. pneumoniae expresses and secretes the surface 
endonuclease, EndA.  The surface nuclease is more often known for its role in DNA 
transport during transformation.
 165
  EndA is required for efficient bacterial 
transformation in pneumococcus; strains with deactivating endA mutations exhibit 
transformation efficiencies less than 1% of wild-type strains.  Pneumococcal bacteria are 
naturally transformable,
 64,68,166
 with the ability to take up DNA from the environment 
and incorporate it into its genome.  This action is accelerated during environmental stress, 
such as exposure to antibacterial agents, and drives the genetic diversification of the 
organism.
 185
  As a consequence, through its DNA transport activity, EndA may play a 
significant role in the evolution of virulence elements, antibiotic resistance, or other 
genetic advantages in S. pneumoniae. 
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Another activity of EndA in pneumococcal pathogenesis has been discovered 
more recently.  This involves the evasion of neutrophil extracellular traps (NETs), a new 
paradigm in the host innate immune defense against invading bacterial pathogens.
 77
  
Released at sites of infection by activated neutrophils, NETs consist of a neutrophil DNA 
backbone with embedded antimicrobial peptides, histones and proteases.  The 
extracellular web-like structure of NETs physically traps bacteria and can block S. 
pneumoniae dissemination.  However, the surface nuclease activity of EndA degrades the 
DNA scaffolding of NETs and facilitates pneumococcal escape.
 78
  Mutant S. pneumoniae 
strains lacking EndA activity do not destroy NETs and show decreased virulence in 
mouse models of infection. 
With important activities in transformation and NET evasion, EndA plays a 
complex and multifaceted role in pneumococcal pathogenesis.  The development of 
potent and selective small molecule probes for EndA would facilitate a greater 
understanding of these activities in the development of S. pneumoniae infection. 
Recently, we reported an efficient PicoGreen nuclease assay for medium-
throughput screening of compound libraries against EndA.
 186
  From a small library 
screen of 4,727 compounds, a number of micromolar hits were identified
186
 and achieved 
a critical initial step in the discovery of a small-molecule probes of EndA.  This 
promising result prompted us to extend the scope of screening to a larger library in order 
to identify new chemical series and expand those resulting from the previous study.
 186
  
Currently in our laboratory, we have access to a 100,000 compound library 
(100K_DivSet) representing a diversity selection from the Enamine’s HTS collection. 187  
Rather than testing the entire library, we decided to use in silico approaches to narrow 
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down the selection of compounds that would be tested in the PicoGreen nuclease assay 
for EndA inhibition. 
In the past decade, virtual screening (VS) proved to be a valuable tool for small-
molecule hit finding
188,189
 with a particular success record on novel targets of uncertain 
drugability.
 190-192
  As such, several complementary VS techniques were employed to 
select potential EndA inhibitors. Virtual screening methods, including a similarity 
search
193,194
 and Naïve Bayesian learning,
 195,196
 were used to capitalize upon the results 
of our previous screening study.
 186
 Thirty-two inhibitors with micromolar IC50 values 
were previously identified and their structures were used to select potentially active 
structures from 100K_DivSet. In addition, a recently solved x-ray structure of EndA
175
 
enabled pharmacophore- and docking-based approaches,
 197,198
 and allowed for selection 
of structurally novel hits.  Finally, we also searched for compounds featuring chelating 
motifs that bind to the metal ion present in the catalytic site of the enzyme.  Here we 
report and discuss how the above approaches were implemented in the context of the 
current project, how well they performed, and conclude with an early stage hit analysis 
that might guide further progress toward a small-molecule tool for probing the role of 
EndA in S. pneumoniae infection. 
A.2. Multiple virtual screening approaches 
 
The main deliverable of a VS campaign is a list of compounds for experimental 
testing in a target-specific assay.  After testing, a successful campaign should find that the 
VS-generated list is significantly enriched in actives, compared to the whole library from 
which the compounds were selected.  However, at the current level of progress, a 
majority of compounds in a typical virtual-hit list are inactive (often referred to as “false 
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positives”).  At the same time, many VS algorithms miss active compounds, while 
instead favoring a specific set of structural or physical properties (often termed as “false 
negatives”).  False negatives are particularly common for ligand-based methods that, by 
definition, select hits analogous to compounds from the training (or query) set.  False 
negatives also occur in docking-based approaches that can neglect actives with less 
studied target-binding phenomena, such as solvation, configurational entropy, or 
polarization. 
A plausible strategy to circumvent the problem of false positives and false 
negatives in VS would be to make use of multiple VS techniques.  In the current study, 
we applied a variety of methods, including 2D similarity search, Bayesian learning, 
pharmacophore models, and docking-based scoring.  To handle multiple techniques, a 
number of “data fusion” 195,199 approaches were developed and benchmarked in order to 
find the best way to combine several hit lists into a single one.  Although technical details 
differentiate data fusion methods, they can be largely distinguished as either consensus- 
or acquiescence-based.  Consensus-based methods are expected to reduce the false 
positives rate by only including compounds designated as “good”.  In contrast, 
acquiescence-based methods address the false negative problem by including compounds 
with few or even one “good” score.  In this VS study, we were interested in creating a 
large list of compounds (~1,000 compounds) with maximum chemical diversity. 
Consequently, in order to maximize the diversity, we employed a simple acquiescence-
based method that involved independent triaging of hit lists produced by individual VS 
techniques followed by a concatenation of the final resulting selections.  The sections 
below detail how each VS method performed and an overview of hits identified. 
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A.3. Ad hoc substructure and pharmacophore search 
 
Chronologically, the first VS method occurred before the EndA 3D structure was 
published and before any inhibitors were identified.  Available to us, was published 
details about EndA structure and function.  Like other restriction enzymes, EndA makes 
use of the Mg
2+
 ion to cleave DNA at its recognition site.
 200
  We therefore hypothesized 
that compounds featuring a chelation motif might strongly bind to the metal ion and 
adjacent fragments could potentially provide specificity to the catalytic site of EndA.  
The substructure queries that we designed were inspired by putative chelators, such as 
ethylenediaminetetraacetic acid (EDTA), or enzyme substrates involved in the Krebs’ 
cycle
201
 that are known to bind divalent metals, such as isocitrate and α-ketoglutarate. We 
could not use a whole multidentate chelator as a query substructure because resulting hits 
would have poor pharmacokinetic profiles.  Instead, we made use of smaller, mostly 
bidentate motifs (Figure A.1a).  We also made use of an endogenous endonuclease 
chelator, NuiA, in a relevant and functional context. The NuiA protein naturally inhibits 
NucA, a cyanobacterial nuclease also belonging to the same ββα Me superfamily of 
nucleases
202
 as EndA.  Therefore, the interactions between NucA and NuiA provided a 
structural template for predicting selective EndA nuclease inhibitors.  It is evident that 
NuiA binds to NucA very locally, with a picomolar affinity, so that only a few NuiA 
residues are interacting with NucA.  This spatial arrangement of the interacting chemical 
groups was coded into a pharmacophore model (Figure A.1b) that also included a few 
more features to purposely interact with the superimposed EndA structure (see Materials 
and Methods for details). 
 125 
Querying the 100K_DivSet with substructures resulted in 316 hits, and the 
pharmacophore search yielded 7,896 hits.  In order to understand the abundance of 
pharmacophore hits, we visually inspected the hits and deduced that the combination of 
the H-bond donor (HBD) and H-bond acceptor (HBA) features often matched an amide 
group that was unlikely to be useful as a chelating agent.  We therefore added a condition 
that the donor feature had to match a hydroxyl group.  This simple sub-structural filter 
drastically reduced the number of the pharmacophore hits to 472 compounds.  At the next 
step, the 316 substructure hits and 472 pharmacophore hits were merged into a single set 
and subjected to clustering and visual triage.  In the end, 320 virtual hits were selected for 
a single-dose screen of a single plate (Plate I) in duplicate.  In composition, Plate I 
contained 79 substructure and 261 pharmacophore hits (20 compounds designated as hits 
by both methods). 
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Figure A.1. Ad hoc and substructure methods of virtual screening for EndA 
inhibitors.  (a) chelating groups used as queries for the substructure search for potential metal-
binding inhibitors; (b) a pharmacophore model built from the NucA (magenta) – NuiA (cyan) 
complex with an addition of EndA-directed features. 
 
A.4. Similarity search and Naïve Bayes learning 
 
We recently reported a medium-throughput screening (MTS) of a small-molecule 
library (4,727 compounds) that resulted in 32 hits.
 186
  The structures of these hits were 
used for recovering their chemical analogs from the 100K_DivSet.  Although it is not 
expected that these analogs would reveal novel chemical motifs, they would, however, 
enrich our knowledge of structure-activity relationships (SAR) and potentially exhibit 
more potent EndA inhibition. 
The main advantage of a similarity search as a VS strategy is that it permits 
exploitation of structures of all known actives without the need to rely upon an estimated 
or a data-derived SAR model.  In this study, similarity searches were performed using all 
known 32 actives as queries.  The substructural fragments, also called fingerprint bits, of 
these 32 actives and all target compounds were counted by the ECFP4 structural 
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fingerprints as implemented in Pipeline Pilot.  Two different similarity search techniques 
were applied: (1) a fingerprint-based similarity search, and (2) a naïve Bayesian classifier 
method.  
The first technique, a fingerprint-based similarity search, was intended to recover 
compounds that are most similar to query compounds.
 194
  The most popular similarity 
metric, the Tanimoto coefficient, was used and determined similarity by dividing the 
count of matching fingerprint bits by the count of non-matching fingerprint bits,
 194
 thus 
normalizing between 0 and 1.  The Tanimoto similarity cutoff was set at 0.55 to ensure a 
reasonable number of search hits (i.e., hundreds) and an adequate chemical diversity. In 
contrast, higher cutoffs tend to result in hits that are too similar to the query structures, 
and afford little additional SAR information. 
In this first approach, every fingerprint bit is given the same weight.  This means 
that some similarity may be selected based on structural fragments that are not necessary, 
or even harmful, for activity.  In particular, this occurs when weakly potent actives are 
used as queries.  Therefore, as an alternative technique we selected another method, naïve 
Bayesian classifier, that makes use of computational analyses that weigh structural 
fragments with respect to their importance for a given biological activity.  In this 
learning-based method, the probability a fragment to occur in an active compound is 
calculated (as a fraction of compounds featuring this fragment among known actives) and 
normalized with respect to the probability for the same fragment to occur in any random 
compound (calculated as a fraction of compounds featuring this fragment within a large 
diverse compound set).  In the Pipeline Pilot software, the weights of individual 
fragments are combined into a single Bayesian score that enables ranking the compounds 
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screened according to fragments featured and their respective weights. Here, a Bayesian 
model was built using a standard “learn good molecules” component as implemented in 
Pipeline Pilot.
 203
  Additionally, a “leave-one-out” cross validation step was included in 
the learning protocol.  The model was learnt using all 32 known actives whose chemical 
structures were represented by means of the ECFP6 structural fingerprints and several 
physical properties (ALogP, molecular weight, Polar Surface Area (PSA), number of 
rotatable bonds, number of H-bond donors and number of H-bond acceptors).  A 
Bayesian score threshold of 12 was used and was found to be optimal in minimizing the 
false positive and false negative rates. 
While the naïve Bayesian classifier has proven to be a powerful VS tool,
 196,204,205
 
learning it on our relatively small set of 32 weakly active compounds was likely to be a 
noisy model with poor predictive power.  Because of this, we applied both the unbiased 
similarity search and the naïve Bayesian classifier in order to improve the odds of 
success.  The unbiased similarity search of the 100K_DivSet, with a Tanimoto coefficient 
threshold of 0.55, resulted in 552 hits.  Concurrently, the naïve Bayesian classifier 
yielded 110 hits with Bayesian scores higher than 12. The 552 similarity hits and 110 
Bayesian hits were merged into a single set and subjected to clustering and visual triage. 
In the end, 320 virtual hits were selected for a single-dose screen on a single plate (Plate 
II) in duplicate. In composition, Plate II contained 250 similarity search-based and 92 
Bayesian hits (22 compounds designated as hits by both methods). 
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A.5. Structure-base screening 
 
When the x-ray crystal structure of the EndA nuclease from Streptococcus 
pneumoniae became available,
 175
 we utilized it for structure-based VS.  The 
identification of EndA’s catalytic site and potential ligand binding pocket was 
straightforward due to the presence of a metal ion.  However, with no other cofactor 
besides the metal ion, the pocket appeared to be quite small and shallow, and presented a 
difficult target for docking-based VS. Indeed, in the absence of a significant van der 
Waals contribution to the GlideScore,
 206
 its value was dominated by metal-binding and 
the H-bond terms. These latter terms contributed to a significant overestimation of the 
binding affinity and the insufficient treatment of the solvation effect. To address this 
issue, we customized GlideScore by exploiting available structure-activity data. More 
specifically, we docked the 4,727 compounds already screened against EndA (32 actives 
identified) and used the calculated terms constituting GlideScore (i.e., lipophilic, van der 
Waals, metal, H-bond, electrostatic and entropic) to train a naïve Bayesian classifier.  By 
doing such, we were able to better score against the specific target without compromising 
the structural novelty of potential hits. 
All compounds from the 100K_DivSet were docked to the catalytic site of EndA 
and the three top-scoring poses were retained for each ligand.  The terms contributing to 
the GlideScore were then used to learn a naïve Bayesian classifier to distinguish between 
the poses of active and inactive compounds.  Two sets of compounds, one containing 300 
GlideScore-based top-scoring ligands and another containing 300 Bayesian top-scorers, 
were selected and merged together for subsequent clustering and visual triage.  In the 
end, 320 virtual hits were selected for a single-dose screen on a single plate (Plate III) in 
duplicate.  Plate III was composed of 92 GlideScore-based and 228 bayesian hits. 
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A.6. Hit analysis 
 
 
Of the total 960 experimentally tested compounds, 22 demonstrated reliable dose-
dependent responses with inhibitory potencies ranging from 4.3 µM to 24 µM (Figure 
A.2, Table A.3).  Remarkably, this hit rate (22 / 960  100 = 2.29%) is not much higher 
than that obtained in our previous screening of a small kinase-targeted library (31 hit / 
4,727 screened  100 = 0.66%).  This comparison prompted us to rigorously assess the 
efficiency of the VS campaign as compared to the performance of random screening.  To 
this end, we randomly selected plates (3,200 compounds total) for testing in the EndA 
assay and did not yield any active compounds.  Although this result did not allow for an 
accurate comparison, it does suggest the VS hit rate was much greater than the rate in a 
random selection screen.  Another interesting question is why the hit rate in the kinase-
targeted library screen
114
 (2.29%) was ~20-fold higher than that of 100K_DivSet random 
selection screen (~0.03%), but is beyond the scope of this discussion.  The 22 actives 
identified from the VS techniques represent 11 distinct chemical families.  The largest 
family (family 3) features a propenyl-quinoline-4-carboxylate motif and is represented by 
10 compounds. Another family (family 1) features a benzothiazol-2-yl-butenone moiety 
and contains 3 compounds. The other 9 families are represented by one compound each 
(see Table A.1 for family classifications). 
The different VS techniques contributed differently to the overall pool of hits. 
Two hits were identified on Plate I; compound 1 resulted from the sub-structural search 
and compound 2 was a pharmacophore hit. Interestingly, compound 1 belongs to a family 
(family 1) that also contains 2 similarity-based hits from Plate II (compounds 14 and 15). 
These hits (compounds 14 and 15) do not feature a carbonyl group adjacent to the 
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benzothiazol group and likely explains why they did not match the substructural metal-
binding query.  Plate II yielded 17 experimentally confirmed hits. The majority of hits 
(14 compounds) resulted from naiive Bayesian classifier, while 5 compounds were from 
the unbiased similarity search (2 compounds were identified by both methods).  Although 
the Bayesian hits largely outnumbered those provided by the similarity search, they 
demonstrate a deceptive lack of chemical diversity. Indeed, 10 of 14 Bayesian hits belong 
to a single family (family 3), while the 4 similarity hits all belong to different families. 
Such a striking difference between the unbiased similarity search and Bayesian-based 
outcomes may be explained by the different nature of the scores that were used to rank 
the respective virtual hits.  The Bayesian score is a result of a learning process and 
reflects the similarity to a composite fingerprint of a virtual generic active, whereas the 
top similarity hits may have originated from multiple diverse query compounds.  Hence, 
the top-ranked Bayesian hits are much more likely to be structurally uniform because 
they match the same “active” fingerprint.  Finally, Plate III contributed 3 experimentally 
confirmed hits. One confirmed hit (compound 18) was selected by the GlideScore and 
custom GlideScore, while Bayesian scoring chose the other two.  All three structure-
based hits are chemically unique and have no similarity to the EndA inhibitors identified 
in our previous study.
 186
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Figure A.2. Structures of 22 experimentally confirmed active compounds. 
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Table A.1. Twenty two experimentally confirmed hits: inhibitory potencies, origin 
and chemical families. 
N EndA IC50 [µM] Plate Method
* Family 
1 27±0.95(2) I Substr 1 
2 21 I Phph 2 
3 24±0.59(3) II Bayes 3 
4 9.7±0.67(3) II Bayes 3 
5 11±1.4(3) II Bayes 3 
6 17±6.9(4) II Bayes 3 
7 7.7±1.1(3) II Bayes 3 
8 9.8±0.77(3) II Bayes 3 
9 13±0.70(3) II Bayes 3 
10 16±5.8(4) II Bayes 3 
11 11±0.85(3) II Bayes 3 
12 5.7±0.16(3) II Sim & Bayes 3 
13 8.4±0.38(3) II Bayes 4 
14 17±0.63(3) II Sim 1 
15 5.7±0.16(3) II Sim & Bayes 1 
16 22±1.8(4) II Bayes 5 
17 4.3±1.2(3) II Sim 6 
18 22±1.8(4) II Bayes 7 
19 14±0.44(4) II Sim 8 
20 13±1.4(7) III Glide 9 
21 30 III Glide/Bayes 10 
22 20±3.9(7) III Glide/Bayes 11 
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A.7. Conclusions 
 
A set of complementary VS techniques was applied to identify novel inhibitors of 
EndA, a surface endonuclease that is an important virulence factor of Streptococcus 
pneumoniae.  The VS techniques cleverly chosen were intended to take advantage either 
of the protein structure and function or the chemical structures of EndA inhibitors 
identified in our previous study.
 186
  
A total of 960 compounds were selected from a diverse library of 100,000 
compounds and tested in a PicoGreen nuclease assay.  Twenty-two experimentally tested 
compounds demonstrated a dose-dependent inhibitory effect.  The inhibitory potency of 
the hits identified, ranging from 4.3 µM to 24 µM, need further improvement, but these 
hits serve as valuable starting points for a hit-to-lead process.  As expected, each VS 
technique contributed hits to the total pool of 22 active compounds. The unbiased 
similarity search and naïve Bayesian classifier methods, both based upon known 
inhibitors, selected the majority of hits in terms of numbers but not in terms of novelty 
and chemical diversity.  Furthermore, an additional screening of a random selection of 
3,200 compounds from the 100K_DivSet did not yield any hits and demonstrated a 
significant efficiency in virtual screening compared to random screening. 
A.8. Materials and methods 
 
 
A.8.1. PicoGreen Nuclease Assay 
Compounds for the primary single-dose runs were resuspended to 1 mM in 
DMSO in barcoded glass vials and sonicated using a Covaris S2 (Covaris, Woburn, MA). 
The compounds were plated at 1 L in 384-well V-bottom polypropylene microplates 
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(Greiner, Monroe, NC) using a Tecan Genesis (Tecan, Münnedorf, Switzerland). On the 
day of use, the compounds were prepared for screening by diluting 10-fold in 1x R Buffer 
(Reaction Buffer: 25 mM imidazole, 20 mM Tris-HCl pH 8.0, 10 mM sodium acetate, 10 
mM MES, 25 mM NaCl, 5 mM MgCl2 , 1.5 M BSA, and 0.01% v/v Triton X-100) and 
1 L of the diluted compounds were spotted into 384-well Proxiplates by a Multimek NS 
X-1536 fitted with a 394-channel head (Nanoscreen, Charleston, SC). In the Proxiplates, 
4.5 L of 2x EndA(H160G) in R Buffer was added to each well.  Following a 20 min 
pre-incubation, 4.5 L of 2x  DNA (HindIII digest) was added to initiate the assay. The 
PicoGreen assay was performed as previously described.
 186
  ScreenAble software 
(Screening Solutions LLC, Chapel Hill, NC) was used to calculate the relative inhibition 
of the primary single-dose run data. Compounds with > 40% relative inhibition, which 
represented more than 4 standard deviations away from the minimum signal control, were 
selected for subsequent dose-response runs. Compounds for the dose-response runs were 
resuspended to 3 mM in DMSO in barcoded vials and plated as 3-fold dilution over 10 
points in 384-well V-bottom microplates. On the day of use, compound titrations were 
diluted as above and PicoGreen assay was performed as described previously. Dose-
response runs were analyzed as above and IC50 values were calculated using four-
parameter fits or using three-parameter fixed top fits as necessary. 
 
A.8.2. Screening library 
All virtual screening runs and experimental testing were performed on a diverse 
screening set of 100,000 compounds (100K_DivSet) available at the Center for 
Integrative Chemical Biology and Drug Discovery. All compounds were purchased from 
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Enamine
187
 and satisfied a softened version of the Lipinski rule
207
 (>2 violations of H-
bond donors <6, H-bond acceptors <12, molecular weight between 200 and 600, ALogP 
<5.5) and rapid elimination of swill (REOS).
 110
  Chemical structures of all screened 
compounds were cleaned using PipelinePilot software.
 203
  The cleaning protocol 
included salt stripping, mixture splitting, functional group standardization and charge 
neutralization. Ionizable compounds were converted to their most probable charged 
species at pH 7.4. Pipeline Pilot was then used for 3D conversion. 
 
A.8.3. 2D substructure and similarity search 
Substructure searches were performed by means of the Pipeline Pilot software using 
a “Substructure Filter from File” component with the MatchType parameter set to 
“MatchAny” and the option “Stereo atoms can map nonstereo atoms” was set to “true”. 
The “Substructure Filter…” component made use of query structures read from 
individual mol files (one substructure per file). 
Similarity searches were performed by means of the Pipeline Pilot software using a 
“Molecular similarity” component with the following key parameter settings: 
SimilarityCoefficient=’Tanimoto’; UseProperties =’FCFP_4’; MinimumSimilarity=’0.4’. 
The query structures were read from a separate SD file. The similarity score of a given 
virtual hit was defined as a Tanimoto similarity to the closest query structure. The 
Accelrys’ proprietary FCFP_4 descriptors (Functional Connectivity FingerPrints of 
diameter = 4) are atom-centered fragments capturing the atom and bond types up to the 
second atomic neighborhood (in case of diameter = 4). Each atom was categorized as one 
of the following: H-bond donor, H-bond acceptor, positively ionized or positively 
ionizable, negatively ionized or negatively ionizable, aromatic or halogen. 
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A.8.4. Pharmacophore screening 
The pharmacophore model was prepared using the Discovery Studio 2.5 software. 
We made use of the high-resolution crystal structure of the NucA:NuiA complex (PDB 
code: 2O3B)
 202
 with a superposed EndA structure (PDB code: 3OWV).
 175
  In addition to 
the existing interactions between NucA/EndA and the inhibitor NuiA, we added features 
expected to bind to EndA in the vicinity of the catalytic metal ion: (i) cation or H-bond 
donor interacting with Glu205; (ii) an additional H-bond acceptor interacting with the 
metal ion; and (iii) two hydrophobic sites intended to complement the shape of the EndA 
catalytic site. The precision spheres of the pharmacophoric features (i.e., regions of space 
to which a virtual hit should fit to) were set to 1 Å. 
The pharmacophore screening of the small-molecule set of procurable compounds 
was performed by means of the Catalyst module of the Discovery Studio 2.5 suite.
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Catalyst was parameterized and controlled by means of a Pipeline Pilot component 
“Ligand-Pharmacophore Map”. The 3D conformations of mapped ligands mapped were 
generated by means of the “3D conformations” component allowing up to 100 
conformers per molecule. The enumerated conformers were then rigidly fitted against the 
pharmacophore. 
 
A.8.5. Naïve Bayes Classifier 
A Naïve Bayesian classifier was employed to learn essential structural features of 
the known active compounds. It provides a simple but efficient machine learning 
technique. Using this classification system, the conditional probability P(A|F) of a 
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compound featuring a fragment F to be active was calculated according to the Bayes 
theorem as: 
             
where P(F|A) is the probability for an active compound to feature a fragment F, P(A) is 
the probability for a compound to be active, and P(F) is the probability for a compound to 
feature the fragment F. The “naïve” qualifier reflects the assumption that fragments were 
not correlated. In this study, we made use of the Naïve Bayesian classifier 
implementation in the Pipeline Pilot component “Learn good molecules”. Following 
Pipeline Pilot implementation, a composite score depending on the number of “good” 
fragments featured by a compound was determined. All models built in this study were 
subjected to a cross-validation process. 
 
A.8.6. Docking-based screening 
Small-molecule structures were docked into the active site of the target proteins 
using the Glide program
206
 in standard docking precision (Glide SP). The binding region 
was defined by a 10Å × 10Å × 10Å box centered on a reference ligand. A scaling factor 
of 0.8 was applied to the van der Waals radii, and default settings were used for all the 
remaining parameters. The top 3 poses were generated for each ligand for the SPLIF 
rescoring. 
 
A.8.7. Hit triage 
After initial hit sets were selected based on a combination of Glide and SPLIF 
scores, Pipeline Pilot software
203
 was used to designate a final selection for screening. 
The virtual hits were first selected by diversity and further refined on an ad hoc basis. 
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Diversity-based selections were performed in two steps.  First, an automated redundancy 
reduction was performed by selecting a single representative of a small similarity-based 
cluster.  The compounds in such a cluster should be similar at ≥65% (Tanimoto with 
ECFP4 fingerprints). In the second step, compounds were clustered into broader families 
by means of the Maximum Common Substructure (MCS) method.  Twenty to 50% of 
compounds were then selected from each cluster in such a way that larger clusters 
contributed smaller percentages.  The output ligands were aligned to their respective 
MCS to facilitate an ad hoc selection. 
 
A.8.8. Quality control of compound samples 
Quality control of the plate containing the screened compounds was performed by 
diluting 1 µL of DMSO stock solution (10mM concentration) with 49 µL of MeOH.  The 
sealed plate was then directly used to inject 5 µL from each well onto an Agilent 6110 
Series LC/MS system with the UV detector set to 220 nm.  Samples were injected onto 
an Agilent Eclipse Plus 4.6 × 50 mm, 1.8 µM, C18 column at room temperature.  A 
mobile phase of A being H2O + 0.1% acetic acid and B being MeOH + 0.1% acetic acid 
was used. A linear gradient from 10% to 100% B in 5.0 min was followed by pumping 
100% B for another 2 minutes with a flow rate of 1.0 mL/min.  Mass spectra  data were 
acquired in positive ion mode using an Agilent 6110 single quadrupole mass 
spectrometer with an electrospray ionization source.  The purity of all compounds was 
found to be 95% or higher. 
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